<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients - Zhang, L - 2014 | Cochrane Library</title> <meta content="Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients - Zhang, L - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009120.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients - Zhang, L - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009120.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009120.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients" name="citation_title"/> <meta content="Ling Zhang" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="zhanglinglzy@163.com" name="citation_author_email"/> <meta content="Xiaoxi Zeng" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Ping Fu" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Hong Mei Wu" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD009120.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/06/23" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009120.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009120.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009120.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Peritoneal Dialysis; Angiotensin Receptor Antagonists [*therapeutic use]; Angiotensin‐Converting Enzyme Inhibitors [*therapeutic use]; Antihypertensive Agents [*therapeutic use]; Disease Progression; Kidney [*drug effects, physiopathology]; Kidney Failure, Chronic [*therapy]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009120.pub2&amp;doi=10.1002/14651858.CD009120.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009120.pub2&amp;doi=10.1002/14651858.CD009120.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009120.pub2&amp;doi=10.1002/14651858.CD009120.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009120.pub2&amp;doi=10.1002/14651858.CD009120.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009120.pub2&amp;doi=10.1002/14651858.CD009120.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009120.pub2&amp;doi=10.1002/14651858.CD009120.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009120.pub2&amp;doi=10.1002/14651858.CD009120.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009120.pub2&amp;doi=10.1002/14651858.CD009120.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009120.pub2&amp;doi=10.1002/14651858.CD009120.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009120.pub2&amp;doi=10.1002/14651858.CD009120.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009120.pub2&amp;doi=10.1002/14651858.CD009120.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009120.pub2&amp;doi=10.1002/14651858.CD009120.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009120.pub2&amp;doi=10.1002/14651858.CD009120.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009120.pub2&amp;doi=10.1002/14651858.CD009120.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009120.pub2&amp;doi=10.1002/14651858.CD009120.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009120.pub2&amp;doi=10.1002/14651858.CD009120.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009120.pub2&amp;doi=10.1002/14651858.CD009120.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009120.pub2&amp;doi=10.1002/14651858.CD009120.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009120.pub2&amp;doi=10.1002/14651858.CD009120.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009120.pub2&amp;doi=10.1002/14651858.CD009120.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009120.pub2&amp;doi=10.1002/14651858.CD009120.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009120.pub2&amp;doi=10.1002/14651858.CD009120.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009120.pub2&amp;doi=10.1002/14651858.CD009120.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="1pyM3CVc";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009120\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009120\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009120\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009120\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009120.pub2",title:"Angiotensin\\u2010converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients",firstPublishedDate:"Jun 23, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1pyM3CVc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009120.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009120.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009120.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009120.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009120.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009120.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009120.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009120.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009120.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009120.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2494 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009120.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009120.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009120.pub2/full#CD009120-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009120.pub2/full#CD009120-sec-0084"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009120.pub2/full#CD009120-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009120.pub2/full#CD009120-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009120.pub2/full#CD009120-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009120.pub2/full#CD009120-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009120.pub2/full#CD009120-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009120.pub2/full#CD009120-sec-0078"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009120.pub2/appendices#CD009120-sec-0089"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/table_n/CD009120StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/table_n/CD009120StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009120.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009120.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009120.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009120.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009120.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009120.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009120.pub2/information#CD009120-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Ling Zhang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009120.pub2/information#CD009120-cr-0003">Xiaoxi Zeng</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009120.pub2/information#CD009120-cr-0004">Ping Fu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009120.pub2/information#CD009120-cr-0005">Hong Mei Wu</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/information/en#CD009120-sec-0099">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 23 June 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009120.pub2">https://doi.org/10.1002/14651858.CD009120.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009120-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009120-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009120-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009120-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009120-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009120-abs-0001" lang="en"> <section id="CD009120-sec-0001"> <h3 class="title" id="CD009120-sec-0001">Background</h3> <p>Angiotensin‐converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) are widely used in peritoneal dialysis (PD) patients, yet controversy exists about their impact on residual kidney function. </p> </section> <section id="CD009120-sec-0002"> <h3 class="title" id="CD009120-sec-0002">Objectives</h3> <p>This review aimed to evaluate the benefits and harms of ACEis and ARBs for preserving residual kidney function in PD patients. </p> </section> <section id="CD009120-sec-0003"> <h3 class="title" id="CD009120-sec-0003">Search methods</h3> <p>The Cochrane Renal Group's specialised register, Cochrane Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE (OvidSP interface), Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI) and other resources were searched by applying a prespecified comprehensive search strategy. Date of last search: 01 May 2014. </p> </section> <section id="CD009120-sec-0004"> <h3 class="title" id="CD009120-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) and quasi‐RCTs comparing ACEis or ARBs with placebo, other antihypertensive drugs or each other in PD patients were included. </p> </section> <section id="CD009120-sec-0005"> <h3 class="title" id="CD009120-sec-0005">Data collection and analysis</h3> <p>Screening, selection, data extraction and quality assessments for each retrieved article were carried out by two authors using standardised forms. Authors were contacted when published data were incomplete. Statistical analyses were performed using the random effects model and results expressed as risk ratio (RR) with 95% confidence intervals (CI). Heterogeneity among studies was explored using the Cochran Q statistic and the I² test, subgroup analyses and random effects meta‐regression. </p> </section> <section id="CD009120-sec-0006"> <h3 class="title" id="CD009120-sec-0006">Main results</h3> <p>Six open‐label studies (257 patients) were identified. One study compared ACEi with other antihypertensive drugs, three compared ARBs with other antihypertensive drugs, and two studies compared an ARB with an ACEi. Long‐term use (≥ 12 months) of an ARB showed significantly benefit of preserving residual kidney function in continuous ambulatory PD (CAPD) patients (MD 1.11 mL/min/1.73 m², 95% CI 0.38 to 1.83), although there was no significant benefit when an ARB were used short‐term (≤ six months). One study showed that compared with other antihypertensive drugs, long‐term use (12 months) of the ACEi ramipril showed a significant reduction in the decline of residual kidney function in patients on CAPD (MD ‐0.93 mL/min/1.73m², 95% CI ‐0.75 to ‐0.11), and delayed the progression to complete anuria (RR 0.64, 95% CI 0.41 to 0.99). There was no significant difference in serum potassium, urinary protein excretion, Kt/V, weekly creatinine clearance and blood pressure for ARBs versus other antihypertensive drugs. Compared with other antihypertensive drugs, ramipril showed no difference in mortality and cardiovascular events. Compared with an ACEi, ARBs did not show any difference in residual kidney function. </p> <p>The selection bias assessment was low in four studies and unclear in two. Five studies were open‐label; however the primary outcome (residual kidney function) was obtained objectively from laboratory tests, and were not likely to be influenced by the lack of blinding. Reporting bias was unclear in all six studies. </p> </section> <section id="CD009120-sec-0007"> <h3 class="title" id="CD009120-sec-0007">Authors' conclusions</h3> <p>Compared with other antihypertensive drugs, long‐term use (≥ 12 months) of ACEis or ARBs showed additional benefits of preserving residual kidney function in CAPD patients. There was no significant difference on residual kidney function preservation between ARBs and ACEis. However, limited by the small number of RCTs enrolling small number of participants, there is currently insufficient evidence to support the use of an ACEi or an ARB as first line antihypertensive therapy in PD patients. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009120-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009120-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009120-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009120-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009120-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009120-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009120-abs-0004">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009120-abs-0003" lang="en"> <h3>Angiotensin‐converting enzyme inhibitors and angiotensin‐II receptor blockers for preserving residual kidney function in peritoneal dialysis patients </h3> <p>Residual kidney function plays a key role in the health and quality of life of patients on peritoneal dialysis (PD). Better preservation of residual kidney function is associated with decreased mortality, even at 1 mL/min of residual glomerular filtration rate (GFR), which is associated with a nearly 50% reduction in mortality rate. Two kinds of antihypertensive drugs, angiotensin‐converting enzyme inhibitors (ACEis) and angiotensin‐II receptor blockers (ARBs), are frequently prescribed for PD patients (primarily to control hypertension or heart failure), and could provide significant cardiovascular benefit for ESKD patients. Nowadays, while ACEis and ARBs use is advocated in PD patients, the supporting evidence is still unclear. However studies have focused on heart protection rather than residual kidney function. The aim of this review was to assess the benefits and harms of ACEis and ARBs therapy for preserving residual kidney function in PD patients. Six studies (257 patients) were included (three ARB studies, one ACEi study and ACEi versus ARB studies). Long‐term use (12 months or more) of an ARB showed a significant benefit in preserving residual kidney function in continuous ambulatory PD (CAPD) patients compared with other antihypertensive drugs, although there was no significant benefit when an ARB were used for less than six months). One study showed that compared with other antihypertensive drugs, long‐term use of the ACEi ramipril showed a significant reduction in the decline of residual kidney function in patients on CAPD as well as anuria rate. While dizziness and cough are the main adverse events when an ACEi is used, only one study comparing an ARB with an ACEi reported this outcome and no significant difference between the two groups were found. While the use of an ARB or an ACEi may both be useful in preserving residual kidney function, the small number of studies and small number of patients enrolled means there is currently insufficient evidence to support the use of an ACEi or an ARB as first line antihypertensive therapy in PD patients. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009120-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009120-sec-0084"></div> <h3 class="title" id="CD009120-sec-0085">Implications for practice</h3> <section id="CD009120-sec-0085"> <p>Compared with other antihypertensive drugs, long‐term use (≥ 12 months) of an ACEi or an ARB showed additional benefits of preserving residual kidney function in CAPD patients. However, limited by the small number of RCTs enrolling small number of participants, there is currently insufficient evidence to support the use of an ACEi or an ARB as first line antihypertensive therapy in PD patients. </p> </section> <h3 class="title" id="CD009120-sec-0086">Implications for research</h3> <section id="CD009120-sec-0086"> <p>More high quality RCTs are needed to evaluate the benefits and harms of ACEis and ARBs for preserving residual kidney function in PD patients. We recommend addressing the following issues in future studies. </p> <p> <ul id="CD009120-list-0009"> <li> <p>Register trials before implementation</p> </li> <li> <p>Describe the process of randomised allocation and allocation concealment in detail</p> </li> <li> <p>Apply blinding when appropriate</p> </li> <li> <p>Put restrictions on parameters that might greatly influence the outcomes (i.e. PD schedule and dosage of ACEis or ARBs) when setting up the inclusion and exclusion criteria </p> </li> <li> <p>Report short‐term and long‐term outcomes of clinical significance, such as mortality, residual kidney function, urine volume and adverse events </p> </li> <li> <p>There are two ongoing studies that are likely to provide useful information to determine which drug (ACEis or ARBs or both) provides better protection of residual kidney function. <a href="./references#CD009120-bbs2-0017" title="NCT00721773 . Effects of benazepril, valsartan or combination of both on residual renal function in peritoneal dialysis patients. http://clinicaltrials.gov/ct2/show/NCT00721773 (accessed 12 June 2014). ">NCT00721773</a> will evaluate the effects of effects of benazepril, valsartan or combination of both on residual kidney function in PD patients; and <a href="./references#CD009120-bbs2-0018" title="NCT01041963 . The effect of enalapril and losartan on peritoneal membrane in continuous ambulatory peritoneal dialysis patients. http://clinicaltrials.gov/ct2/show/NCT01041963 (accessed 12 June 2014). ">NCT01041963</a> will study the effect of enalapril and losartan on peritoneal membrane in CAPD patients. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009120-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009120-sec-0022"></div> <div class="table" id="CD009120-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Angiotensin receptor blockers (ARBs) versus conventional therapy for preserving residual kidney function in peritoneal dialysis patients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ARBs versus conventional therapy for preserving residual kidney function in peritoneal dialysis patients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients receiving PD </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> ARB </p> <p><b>Comparison:</b> Conventional therapy </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Conventional therapy</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>ARBs</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Residual kidney function (3 months)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean across control group was 3.06 mL/min/1.73 m²</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean was on average <b>0.44 mL/min/1.73 m</b> ² <b>lower</b> (95% Cl ‐1.53 to 0.65) in the ARB group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Residual kidney function (6 months)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean across control group was 2.26 mL/min/1.73 m²</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean was on average <b>0.20 mL/min/1.73 m</b> ² <b>lower</b> (95% Cl ‐1.01 to 0.61) in the ARB group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Residual kidney function (≥ 12 months)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean across control groups ranged from 1.04 to 2.8 mL/min/1.73 m²</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean was on average <b>1.11 mL/min/1.73 m</b> ² <b>lower</b> (95% Cl 0.38 to 1.83) in the ARB groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Residual kidney function (12 months)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean across control group was 1.04 mL/min/1.73 m²</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean was on average <b>0.64 mL/min/1.73 m</b> ² <b>higher</b> (95% Cl 0.19 to 1.19) in the ARB group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Residual kidney function (24 months)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean across control groups ranged from 2.57 to 2.8 mL/min/1.73 m²</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean was on average<b>1.49 mL/min/1.73 m</b> ² <b>higher</b> (95% Cl 1.12 to 1.86) in the ARB groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urinary protein excretion</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean across control groups ranged from 1.12 to 2.97 g/24 h</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean was on average<b>0.01 g/24 h lower</b> (95% Cl ‐0.09 to 0.06) in the ARB groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Kt/V</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean Kt/V across control groups ranged from 1.69 to 1.98</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean was on average<b>0.1 higher</b> (95% Cl ‐0.02 to 0.22) in the ARB groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weekly creatinine clearance</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean across control groups from 31.4 to 71.5 L/wk/1.73 m²</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean was on average<b>9.06 L/wk/1.73 m</b> ² <b>higher</b> (95% Cl ‐2.77 to 20.90) in the ARB groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Systolic BP</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean across control groups ranged from 129 to 137 mm Hg</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean was on average<b>‐0.67 mm Hg higher</b> (95% Cl ‐2.77 to 1.42) in the ARB groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diastolic BP</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean across control groups ranged from 129 to 137 mm Hg</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean was on average<b>‐0.70 mm Hg higher</b> (95% Cl ‐2.14 to 0.74) in the ARB groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum potassium</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean across control group was 4.06 mmol/L</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean was on average<b>0.13 mmol/L higher</b> (95% Cl ‐0.12 to 0.38) in the ARB group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events (episodes of peritonitis)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.67</b> (0.18 to 2.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD009120-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Angiotensin‐converting enzyme inhibitors (ACEi) versus conventional therapy for preserving residual kidney function in peritoneal dialysis patients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ACEi versus conventional therapy for preserving residual kidney function in peritoneal dialysis patients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients receiving PD </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> ACEi </p> <p><b>Comparison:</b> Conventional therapy </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Conventional therapy</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ACEi</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Decline in residual kidney function (12 months)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean across the control group was 1.86 mL/min/1.73 m²</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean was <b>0.93 mL/min/1.73 m</b> ² <b>lower</b>(95% Cl ‐1.75 to ‐0.11) in the ACEi group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Anuria</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>High risk population</b> </p> <p><b>733 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>467 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.32</b> </p> <p>(0.11 to 0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.50</b> </p> <p>(0.27 to 8.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cardiac events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.0</b> </p> <p>(0.37 to 3.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cardiac events (fatal)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.0</b> </p> <p>(0.15 to 6.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cardiac events (non fatal)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.0</b> </p> <p>(0.31 to 3.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events (episodes of peritonitis)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.13</b> </p> <p>(0.47 to 2.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events (episodes of peritonitis) ‐ treated with an aminoglycoside</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.20</b> </p> <p>(0.41 to 3.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events (episodes of peritonitis) ‐ not treated with an aminoglycoside</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.00</b> </p> <p>(0.22 to 4.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD009120-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Angiotensin receptor blockers (ARBs) versus angiotensin‐converting enzyme inhibitors (ACEis) for preserving residual kidney function in peritoneal dialysis patients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ARBs compared with ACEis for preserving residual kidney function in peritoneal dialysis patients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients receiving PD </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> ARB </p> <p><b>Comparison:</b> ACEi </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>ACEi</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>ARB</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Residual kidney function (4 weeks)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean across ACEi group was 2.28 mL/min/1.73 m²</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean was <b>0.47 mL/min/1.73 m</b> ² <b>lower</b> (95% Cl ‐2.73 to 1.79) in the ARB group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Residual kidney function (12 months)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean across ACEi group was 2.36 mL/min/1.73 m²</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean was <b>0.18 mL/min/1.73 m</b> ² <b>higher</b> (95% Cl ‐0.04 to 0.40) in the ARB group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Anuria</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>High risk population</b> </p> <p><b>367 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>400 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.15</b> (0.41 to 3.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiovascular events (non‐fatal)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>High risk population</b> </p> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>133 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.33</b> (0.33 to 5.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serum potassium</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean across ACEi group was 4.42 mmol/L</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean was <b>0.05 mmol/L lower</b> (95% Cl ‐2.73 to 1.79) in the ARB group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systolic BP</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean across ACEi group was 141.95 mm Hg</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean was <b>0.48 mm Hg higher</b> (95% Cl ‐7.76 to 8.72) in the ARB group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Diastolic BP</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean across ACEi group was 84.19 mm Hg</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean was <b>0.38 mm Hg higher</b> (95% Cl ‐6.76 to 7.52) in the ARB group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cough</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>High risk population</b> </p> <p><b>67 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>100 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.56</b> </p> <p>(0.24 to 10.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hyperkalaemia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>High risk population</b> </p> <p><b>69 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>83 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.23</b> (0.35 to 4.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>144 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009120-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009120-sec-0023"></div> <section id="CD009120-sec-0024"> <h3 class="title" id="CD009120-sec-0024">Description of the condition</h3> <p>Peritoneal dialysis (PD) has been established for more than 30 years as a form of renal replacement therapy (RRT). Improvements in continuous ambulatory/cyclic PD (CAPD/CCPD) have resulted in its widespread adoption for treating end‐stage kidney disease (ESKD). Cost comparisons between PD and haemodialysis (HD) show that PD is less expensive than HD (<a href="./references#CD009120-bbs2-0021" title="BlakePG . Integrated end‐stage renal disease care: the role of peritoneal dialysis. Nephrology Dialysis Transplantation2001;16 Suppl 5:61‐6. [MEDLINE: 11509687] ">Blake 2001</a>). In the United States, 8% of the ESKD population is on PD (<a href="./references#CD009120-bbs2-0045" title="US Renal Data System. USRDS 2003 annual report: atlas of end‐stage renal disease in the United States. Bethesda, MD, 2003. http://www.usrds.org/atlas03.aspx (accessed 12 June 2014):78‐80. ">USRDS 2003</a>), but it is more prevalent in other countries: Canada (20% to 30%) (<a href="./references#CD009120-bbs2-0038" title="SchaubelDE , FentonSS . Trends in mortality on peritoneal dialysis: Canada. Journal of the American Society of Nephrology2000;11(1):126‐33. [MEDLINE: 10616848] ">Schaubel 2000</a>); Denmark (33%) (<a href="./references#CD009120-bbs2-0027" title="HeafJG , LokkegaardH , MadsenM . Initial survival advantage of peritoneal dialysis relative to haemodialysis. Nephrology Dialysis Transplantation2002;17(1):112‐7. [MEDLINE: 11773473] ">Heaf 2002</a>); Netherlands (39%) (<a href="./references#CD009120-bbs2-0044" title="TermorshuizenF , KorevaarJC , DekkerFW , VanManenJG , BoeschotenEW , KredietRT . Hemodialysis and peritoneal dialysis: comparison of adjusted mortality rates according to the duration of dialysis: analysis of The Netherlands Cooperative Study on the Adequacy of Dialysis. Journal of the American Society of Nephrology2003;14(11):2851‐60. [MEDLINE: 14569095] ">Termorshuizen 2003</a>); Hong Kong (80%) (<a href="./references#CD009120-bbs2-0032" title="LiPK , SzetoCC , LawMC , ChauKF , FungKS , LeungCB , et al. Comparison of double‐bag and Y‐set disconnect systems in continuous ambulatory peritoneal dialysis: a randomized prospective multicenter study. American Journal of Kidney Diseases1999;33(3):535‐40. [MEDLINE: 10070918] ">Li 1999</a>); and Mexico (81%) (<a href="./references#CD009120-bbs2-0023" title="Cueto‐ManzanoAM . Peritoneal dialysis in Mexico. Kidney International2003;83(Suppl):S90‐2. [MEDLINE: 12864882] ">Cueto‐Manzano 2003</a>). Some epidemiological studies have shown an adjusted survival advantage for PD compared with HD during the first two years of dialysis (<a href="./references#CD009120-bbs2-0025" title="FentonSS , SchaubelDE , DesmeulesM , MorrisonHI , MaoY , CoplestonP , et al. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. American Journal of Kidney Diseases1997;30(3):334‐42. [MEDLINE: 9292560] ">Fenton 1997</a>; <a href="./references#CD009120-bbs2-0027" title="HeafJG , LokkegaardH , MadsenM . Initial survival advantage of peritoneal dialysis relative to haemodialysis. Nephrology Dialysis Transplantation2002;17(1):112‐7. [MEDLINE: 11773473] ">Heaf 2002</a>), and several studies have also suggested that CAPD is equivalent to HD or may even be superior for certain subgroups (<a href="./references#CD009120-bbs2-0026" title="GokalR , FiguerasM , OlleA , RoviraJ , BadiaX . Outcomes in peritoneal dialysis and haemodialysis‐a comparative assessment of survival and quality of life. Nephrology Dialysis Transplantation1999;14 Suppl 6:24‐30. [MEDLINE: 10528709] ">Gokal 1999</a>; <a href="./references#CD009120-bbs2-0041" title="SuzukiH , NakamotoH , OkadaH , SugaharaS , KannoY . A selective angiotensin receptor antagonist, Valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness. Advances in Peritoneal Dialysis2003;19:59‐66. [MEDLINE: 14763035] ">Suzuki 2003a</a>). </p> <p>Residual kidney function is better preserved with PD than with HD (<a href="./references#CD009120-bbs2-0022" title="CancariniG , BunoriG , CamereriniC , BrasaS , ManiliL , MaiorcaR . Renal function recovery and maintenance of residual diuresis in CAPD and hemodialysis. Peritoneal Dialysis Bulletin1986;6(2):77‐9. [EMBASE: 1986213696] ">Cancarini 1986</a>) because HD causes substantial haemodynamic disturbance and activates inflammation, which may accelerate the loss of residual kidney function. Patients treated with PD have been shown to have a 65% lower risk for losing residual kidney function than patients receiving HD (<a href="./references#CD009120-bbs2-0036" title="MoistLM , PortFK , OrzolSM , YoungEW , OstbyeT , WolfeRA , et al. Predictors of loss of residual renal function among new dialysis patients. Journal of the American Society of Nephrology2000;11(3):556‐64. [MEDLINE: 10703680] ">Moist 2000</a>). This better preservation, which has been attributed to an effect of residual function on both total solute clearance and fluid status (<a href="./references#CD009120-bbs2-0020" title="BargmanJM , ThorpeKE , ChurchillDN . Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. Journal of the American Society of Nephrology2001;12(10):2158‐62. [MEDLINE: 11562415] ">Bargman 2001</a>), may be an important factor for choosing PD and an important determinant of mortality and morbidity (<a href="./references#CD009120-bbs2-0020" title="BargmanJM , ThorpeKE , ChurchillDN . Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. Journal of the American Society of Nephrology2001;12(10):2158‐62. [MEDLINE: 11562415] ">Bargman 2001</a>; <a href="./references#CD009120-bbs2-0043" title="SzetoCC , WongTY , LeungCB , WangAY , LawMC , LuiSF , et al. Importance of dialysis adequacy in mortality and morbidity of Chinese CAPD patients. Kidney International2000;58(1):400‐7. [MEDLINE: 10886588] ">Szeto 2000</a>). Better preservation is associated with decreased mortality, even at a low level (<a href="./references#CD009120-bbs2-0021" title="BlakePG . Integrated end‐stage renal disease care: the role of peritoneal dialysis. Nephrology Dialysis Transplantation2001;16 Suppl 5:61‐6. [MEDLINE: 11509687] ">Blake 2001</a>; <a href="./references#CD009120-bbs2-0040" title="SheminD , BostomAG , LambertC , HillC , KitsenJ , KligerAS . Residual renal function in a large cohort of peritoneal dialysis patients: change over time, impact on mortality and nutrition. Peritoneal Dialysis International2000;20(4):439‐44. [MEDLINE: 11007376] ">Shemin 2000</a>) with some studies showing that each 1 mL/min of residual glomerular filtration rate (GFR) is associated with a nearly 50% reduction in mortality rate (<a href="./references#CD009120-bbs2-0043" title="SzetoCC , WongTY , LeungCB , WangAY , LawMC , LuiSF , et al. Importance of dialysis adequacy in mortality and morbidity of Chinese CAPD patients. Kidney International2000;58(1):400‐7. [MEDLINE: 10886588] ">Szeto 2000</a>; <a href="./references#CD009120-bbs2-0035" title="MaiorcaR , BrunoriG , ZubaniR , CancariniGC , ManiliL , CameriniC , et al. Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients. A longitudinal study. Nephrology Dialysis Transplantation1995;10(12):2295‐305. [MEDLINE: 8808229] ">Maiorca 1995</a>). It has also been estimated that each 1 mL/min of renal clearance can be translated into a Kt/V of 0.25 to 0.3/wk in a 70 kg man (<a href="./references#CD009120-bbs2-0033" title="LiPK , SzetoCC . Adequacy targets of peritoneal dialysis in the Asian population. Peritoneal Dialysis International2001;21 Suppl 3:S378‐83. [MEDLINE: 11887861] ">Li 2001a</a>; <a href="./references#CD009120-bbs2-0046" title="VenkataramanV , NolphKD . Preservation of residual renal function‐an important goal. Peritoneal Dialysis International2000;20(4):392‐5. [MEDLINE: 11007370] ">Venkataraman 2000</a>). One, 2 L dialysis exchange/d could be spared by preserving 1 mL/min of residual GFR, which could improve quality of life and decrease costs substantially (<a href="./references#CD009120-bbs2-0034" title="LiLP , ChowKM . The cost barrier to peritoneal dialysis in the developing world‐an Asian perspective. Peritoneal Dialysis International2001;2001(21 Suppl 3):S307‐13. [MEDLINE: 11887842] ">Li 2001b</a>). However, the initial survival advantage of PD compared with HD may change to a disadvantage after long‐term PD (<a href="./references#CD009120-bbs2-0044" title="TermorshuizenF , KorevaarJC , DekkerFW , VanManenJG , BoeschotenEW , KredietRT . Hemodialysis and peritoneal dialysis: comparison of adjusted mortality rates according to the duration of dialysis: analysis of The Netherlands Cooperative Study on the Adequacy of Dialysis. Journal of the American Society of Nephrology2003;14(11):2851‐60. [MEDLINE: 14569095] ">Termorshuizen 2003</a>) because of the decrease of residual GFR and the development of peritoneal membrane alterations (<a href="./references#CD009120-bbs2-0047" title="WilliamsJD , CraigKJ , TopleyN , VonRuhlandC , FallonM , NewmanGR , et al. Morphologic changes in the peritoneal membrane of patients with renal disease. Journal of the American Society of Nephrology2002;13(2):470‐9. [MEDLINE: 11805177] ">Williams 2002</a>). As a result, measures to preserve residual kidney function and peritoneal membrane are an important target in the treatment of patients receiving PD. </p> </section> <section id="CD009120-sec-0025"> <h3 class="title" id="CD009120-sec-0025">Description of the intervention</h3> <p>Angiotensin‐converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) are frequently prescribed in PD patients, primarily for the control of hypertension or heart failure, which could provide significant cardiovascular benefit in ESKD patients. A double blind randomised controlled study (RCT) (<a href="./references#CD009120-bbs2-0042" title="SuzukiT , KannoY , NakamotoN , OkadaH , SugaharaS , SuzukiH . Peritoneal dialysis versus hemodialysis: A five‐year comparison of survival and effects on the cardiovascular system, erythropoiesis, and calcium metabolism. Advances in Peritoneal Dialysis2003;19:148‐54. [MEDLINE: 14763052] ">Suzuki 2003b</a>) showed that the ARB valsartan had a beneficial effect on left ventricular hypertrophy in patients on CAPD. Use of an ACEi has also been independently associated with a decreased risk for loss of residual kidney function (<a href="./references#CD009120-bbs2-0036" title="MoistLM , PortFK , OrzolSM , YoungEW , OstbyeT , WolfeRA , et al. Predictors of loss of residual renal function among new dialysis patients. Journal of the American Society of Nephrology2000;11(3):556‐64. [MEDLINE: 10703680] ">Moist 2000</a>). </p> </section> <section id="CD009120-sec-0026"> <h3 class="title" id="CD009120-sec-0026">How the intervention might work</h3> <p>Many studies confirm that both ARBs and ACEis are effective in the prevention of progressive chronic kidney disease and reduction of proteinuria. Recently, some clinical studies have demonstrated positive effects of an ACEi or an ARB on preserving residual kidney function in PD patients (<a href="./references#CD009120-bbs2-0001" title="LiPK , ChowK , WongTY , LeungC , SzetoCC . Effects of an angiotensin‐converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Annals of Internal Medicine2003;139(2):105‐12. [MEDLINE: 12859160] LiPK , ChowK , WongTY , LeungC , SzetoCC . Preservation of residual renal function in peritoneal dialysis patients by angiotensin‐converting‐enzyme inhibitor ‐ a prospective study [abstract no: F‐FC004]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):1a. [CENTRAL: CN‐00446373] ">Li 2003</a>; <a href="./references#CD009120-bbs2-0004" title="SuzukiH , KannoY , SugaharaS . Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. American Journal of Kidney Diseases2004;43(6):1056‐64. [MEDLINE: 15168386] ">Suzuki 2004</a>; <a href="./references#CD009120-bbs2-0006" title="ZhongH , ShaCH , SuiTL , QiuHY , LiuF , QinW , et al. Effects of irbesartan on residual renal function in peritoneal dialysis patients. Chinese Journal of Nephrology2007;23(7):413‐6. ">Zhong 2007a</a>). In addition, the results of a recent study show that ACEis and ARBs were likely to have a membrane protective effect by preventing the increase in small solute transport that often occurs in long term PD which is possibly related to a larger number of perfused peritoneal microvessels (<a href="./references#CD009120-bbs2-0031" title="KolesnykI , DekkerFW , NoordzijM , leCessieS , StruijkDG , KredietRT . Impact of ACE inhibitors and AII receptor blockers on peritoneal membrane transport characteristics in long‐term peritoneal dialysis patients. Peritoneal Dialysis International2007;27(4):446‐53. [MEDLINE: 17602154] ">Kolesnyk 2007</a>). </p> </section> <section id="CD009120-sec-0027"> <h3 class="title" id="CD009120-sec-0027">Why it is important to do this review</h3> <p>A recent systematic review concluded that ACEis and ARBs slow the loss of residual kidney function based on two RCTs enrolling a total of 94 participants (<a href="./references#CD009120-bbs2-0019" title="AkbariA , KnollG , FergusonD , McCormickB , DavisA , BiyaniM . Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers in peritoneal dialysis: systematic review and meta‐analysis of randomized controlled trials. Peritoneal Dialysis International2009;29(5):554–61. [MEDLINE: 19776050] ">Akbari 2009</a>). A more comprehensive systematic review is warranted since only studies published in English were included and it did not provide details on other parameters of great clinical significance such as peritoneal function, changes in blood pressure and quality of life. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009120-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009120-sec-0028"></div> <p>This review aimed to evaluate the benefits and harms of ACEis and ARBs for preserving residual kidney function in PD patients. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009120-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009120-sec-0029"></div> <section id="CD009120-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009120-sec-0031"> <h4 class="title">Types of studies</h4> <p>All RCTs and quasi‐RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) investigating the benefits and harms of ACEi and ARBs for preserving residual kidney function in PD were considered eligible for inclusion, whether or not residual kidney function was set as the primary outcome. However, studies that did not assess residual kidney function were not included. </p> </section> <section id="CD009120-sec-0032"> <h4 class="title">Types of participants</h4> <section id="CD009120-sec-0033"> <h5 class="title">Inclusion criteria</h5> <p>ESKD patients with residual kidney function receiving any type of PD regardless of age, primary diseases and clinical medical course. The definition of remaining or losing residual kidney function applied by each study was accepted. </p> </section> <section id="CD009120-sec-0034"> <h5 class="title">Exclusion criteria</h5> <p> <ol id="CD009120-list-0001"> <li> <p>Acute kidney injury: abrupt (within 48 hours) reduction in kidney function, currently defined as an absolute increase in serum creatinine (SCr) (≥ 0.3 mg/dL or ≥ 26.5 μmol/L), a percentage increase in SCr of ≥ 50% (1.5‐fold from baseline) or a reduction in urine output (documented oliguria of &lt; 0.5 mL/kg/h for &gt; 6 hours) despite adequate fluid resuscitation when applicable. Patients receiving both PD and HD. </p> </li> </ol> </p> </section> </section> <section id="CD009120-sec-0035"> <h4 class="title">Types of interventions</h4> <p>Any ACEi or ARB used for ESKD patients receiving PD, regardless of dosage, mode of administration or duration of treatment. The comparisons were as follows: </p> <p> <ol id="CD009120-list-0002"> <li> <p>ACEi or ARB or both + routine treatment versus routine treatment + placebo</p> </li> <li> <p>ACEi or ARB or both + routine treatment versus routine treatment</p> </li> <li> <p>ACEi or ARB or both+ routine treatment versus routine treatment + other drugs (antihypertensive drugs). </p> </li> <li> <p>ACEi + routine treatment versus ARB + routine treatment</p> </li> </ol> </p> <p>Routine treatment: PD and supportive treatment.</p> <p>Supportive treatment can include approaches to treat underlying kidney or medical diseases and to improve other disorders linked to kidney failure, such as anaemia, calcium and phosphate imbalance, and dyslipidaemia. Supportive treatment should be comparable between study and control groups. </p> </section> <section id="CD009120-sec-0036"> <h4 class="title">Types of outcome measures</h4> <section id="CD009120-sec-0037"> <h5 class="title">Primary outcomes</h5> <p>Residual kidney function (as measured by GFR or endogenous creatinine clearance (CrCl).</p> </section> <section id="CD009120-sec-0038"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD009120-list-0003"> <li> <p>All‐cause mortality</p> </li> <li> <p>Cardiovascular mortality (deaths caused by heart failure, myocardial infarction, stroke or cardiac arrest) </p> </li> <li> <p>Non‐fatal cardiovascular events (non‐fatal myocardial infarction, angina pectoris, stroke and arrhythmia) </p> </li> <li> <p>Urinary albumin/protein excretion rate</p> </li> <li> <p>Anuria</p> </li> <li> <p>Peritoneal function: dialysis adequacy (Kt/V, weekly CrCl), peritoneal membrane transport</p> </li> <li> <p>The number of patients changing from PD to HD or increasing PD dose due to declining of residual kidney function </p> </li> <li> <p>Blood pressure (mm Hg)</p> </li> <li> <p>Quality of life (validated scale/s are required)</p> </li> <li> <p>Adverse events: cough, potassium, hyperkalaemia, hypotension, angioedema and peritonitis.</p> </li> </ol> </p> </section> </section> </section> <section id="CD009120-sec-0039"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD009120-sec-0040"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Renal Group's Specialised Register (to 15 May 2014) through contact with the Trials' Search Co‐ordinator using search terms relevant to this review. The Cochrane Renal Group’s Specialised Register contains studies identified from the following sources. </p> <p> <ol id="CD009120-list-0004"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of renal‐related journals and the proceedings of major renal conferences</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected renal journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of the Cochrane Renal Group. Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available in the Specialised Register section of information about the <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html" target="_blank">Cochrane Renal Group</a>. </p> <p>See <a href="./appendices#CD009120-sec-0090">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD009120-sec-0041"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD009120-list-0005"> <li> <p>Chinese Biomedical Literature Database (CBM)</p> </li> <li> <p>China National Knowledge Infrastructure (CNKI)</p> </li> <li> <p>Reference lists of clinical practice guidelines, review articles and relevant studies</p> </li> <li> <p>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies. </p> </li> </ol> </p> </section> </section> <section id="CD009120-sec-0042"> <h3 class="title" id="CD009120-sec-0042">Data collection and analysis</h3> <section id="CD009120-sec-0043"> <h4 class="title">Selection of studies</h4> <p>The review was undertaken by four authors. The search strategy described was used to obtain titles and abstracts of studies that might be relevant to the review. The titles and abstracts were screened independently by two authors, who discarded studies that were not applicable, however studies and reviews that might include relevant data or information on studies were retained initially. Two authors independently assessed retrieved abstracts (and if necessary the full text) to determine which studies satisfied the inclusion criteria. </p> </section> <section id="CD009120-sec-0044"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently by two authors using standard data extraction forms. Studies reported in non‐English or Non‐Chinese language journals were translated before assessment. Where more than one publication of one study exists, reports were grouped together and the most recent or most complete data set were used. Any discrepancy between published versions were highlighted. Disagreements were resolved in consultation with the other authors. </p> </section> <section id="CD009120-sec-0045"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were assessed using the risk of bias assessment tool (<a href="./references#CD009120-bbs2-0030" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) (see <a href="./appendices#CD009120-sec-0091">Appendix 2</a>). </p> <p> <ul id="CD009120-list-0006"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study (detection bias)? </p> <ul id="CD009120-list-0007"> <li> <p>Participants and personnel</p> </li> <li> <p>Outcome assessors</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> </section> <section id="CD009120-sec-0046"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (mortality, complications of treatment and cardiovascular events) results were expressed as risk ratios (RR) with 95% confidence intervals (CI). Where continuous scales of measurement was used to assess the effects of treatment (e.g. residual kidney function, peritoneal function, blood pressure, proteinuria and urine volume), the mean difference (MD) were used, or the standardised mean difference (SMD) if different scales had been used. </p> </section> <section id="CD009120-sec-0047"> <h4 class="title">Dealing with missing data</h4> <p>Any further information required from the original author was requested by written correspondence and any relevant information obtained in this manner was included in the review. </p> </section> <section id="CD009120-sec-0048"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was analysed using a Chi² test on N‐1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² test (<a href="./references#CD009120-bbs2-0029" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>). I² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity. </p> </section> <section id="CD009120-sec-0049"> <h4 class="title">Assessment of reporting biases</h4> <p>Although we had planned to create funnel plots to assess for the potential existence of small study bias (<a href="./references#CD009120-bbs2-0030" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), the small number of included studies meant that this was not possible. </p> </section> <section id="CD009120-sec-0050"> <h4 class="title">Data synthesis</h4> <p>Data were pooled using the random‐effects model but the fixed‐effect model was also applied to ensure robustness of the model chosen and susceptibility to outliers. </p> </section> <section id="CD009120-sec-0051"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed subgroup analysis to identify possible sources of heterogeneity. Differences in participants (ethnicity, age and underlying kidney diseases) and disparities related to intervention (i.e. the type and dose of ACEi or ARB or both, modality and dose of PD and duration of therapy) might be attributed to heterogeneity. The following subgroup analyses were planned to investigate any observed heterogeneity. </p> <p> <ol id="CD009120-list-0008"> <li> <p>Different underlying kidney diseases (i.e. diabetic kidney disease or non‐diabetic kidney diseases) </p> </li> <li> <p>Different type and dose of ACEi and or ARB</p> </li> <li> <p>Different modalities of PD (i.e. CAPD, CCPD or automated PD)</p> </li> <li> <p>Different durations of therapy and follow‐up.</p> </li> </ol> </p> <p>Adverse effects were tabulated and assessed with descriptive techniques, as they are likely to be different for the various drugs used. Where possible, the risk difference (RD) with 95% CI was calculated for each adverse effect, either compared to no treatment or to another agent. </p> </section> <section id="CD009120-sec-0052"> <h4 class="title">Sensitivity analysis</h4> <p>Where possible, we performed sensitivity analyses to evaluate the effect on the overall result of removing studies with low methodological quality. Studies with inadequate allocation concealment; achieving inadequate follow‐up and unblinded outcome assessment, or blinding of outcome assessment uncertain, were considered as being of low methodological quality. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009120-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009120-sec-0053"></div> <section id="CD009120-sec-0054"> <h3 class="title">Description of studies</h3> <section id="CD009120-sec-0055"> <h4 class="title">Results of the search</h4> <p>After searching the Cochrane Renal Group's Specialised Register (59 records), CENTRAL (13), EMBASE (22), and Chinese databases (15) we identified 109 records. After duplicate removal and removing irrelevant records 26 reports were retained for full‐text assessment. Full‐text assessment identified revealed six eligible studies (seven reports) (<a href="./references#CD009120-bbs2-0001" title="LiPK , ChowK , WongTY , LeungC , SzetoCC . Effects of an angiotensin‐converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Annals of Internal Medicine2003;139(2):105‐12. [MEDLINE: 12859160] LiPK , ChowK , WongTY , LeungC , SzetoCC . Preservation of residual renal function in peritoneal dialysis patients by angiotensin‐converting‐enzyme inhibitor ‐ a prospective study [abstract no: F‐FC004]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):1a. [CENTRAL: CN‐00446373] ">Li 2003</a>; <a href="./references#CD009120-bbs2-0004" title="SuzukiH , KannoY , SugaharaS . Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. American Journal of Kidney Diseases2004;43(6):1056‐64. [MEDLINE: 15168386] ">Suzuki 2004</a>; <a href="./references#CD009120-bbs2-0005" title="WangJ , XiaoMY . Protective effects of valsartan on residual renal function in patients on CAPD. Chinese Journal of Blood Purification2005;4(11):605‐6. ">Wang 2005d</a>; <a href="./references#CD009120-bbs2-0006" title="ZhongH , ShaCH , SuiTL , QiuHY , LiuF , QinW , et al. Effects of irbesartan on residual renal function in peritoneal dialysis patients. Chinese Journal of Nephrology2007;23(7):413‐6. ">Zhong 2007a</a>; <a href="./references#CD009120-bbs2-0002" title="PhakdeekitcharoenB , Leelasa‐nguanP . Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. American Journal of Kidney Diseases2004;44(4):738‐46. [MEDLINE: 15384026] ">Phakdeekitcharoen 2004</a>; <a href="./references#CD009120-bbs2-0003" title="Reyes‐MarinFA , CalzadaC , BallesterosA , AmatoD . Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study. Revista de Investigacion Clinica2012;64(4):315‐21. [MEDLINE: 23227581] ">Reyes‐Marin 2012</a>) with a total of 257 participants. Two of these studies were published in Chinese (<a href="./references#CD009120-bbs2-0005" title="WangJ , XiaoMY . Protective effects of valsartan on residual renal function in patients on CAPD. Chinese Journal of Blood Purification2005;4(11):605‐6. ">Wang 2005d</a>; <a href="./references#CD009120-bbs2-0006" title="ZhongH , ShaCH , SuiTL , QiuHY , LiuF , QinW , et al. Effects of irbesartan on residual renal function in peritoneal dialysis patients. Chinese Journal of Nephrology2007;23(7):413‐6. ">Zhong 2007a</a>). Two reports were classified as ongoing studies (<a href="./references#CD009120-bbs2-0017" title="NCT00721773 . Effects of benazepril, valsartan or combination of both on residual renal function in peritoneal dialysis patients. http://clinicaltrials.gov/ct2/show/NCT00721773 (accessed 12 June 2014). ">NCT00721773</a>; <a href="./references#CD009120-bbs2-0018" title="NCT01041963 . The effect of enalapril and losartan on peritoneal membrane in continuous ambulatory peritoneal dialysis patients. http://clinicaltrials.gov/ct2/show/NCT01041963 (accessed 12 June 2014). ">NCT01041963</a>, one conference abstract is awaiting classification (<a href="./references#CD009120-bbs2-0016" title="MedcalfJF , CarrS , WallsJ , HarrisKP . The effect of ACE Inhibitors and AII receptor antagonists on erythrocytosis in patients on CAPD taking EPO [abstract]. 37th Congress. European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17‐20; Nice, France. 2000:235. [CENTRAL: CN‐00461288] ">Medcalf 2000</a>), and nine studies (16 reports) were excluded (<a href="./references#CD009120-bbs2-0007" title="CioniA , SordiniC , CavalliniI , BigazziR , VitoM , CampeseVM . Angiotensin receptor blocker telmisartan improves insulin sensitivity in peritoneal dialysis patients. Peritoneal Dialysis International2010;30(1):66‐71. [MEDLINE: 20056982] ">Cioni 2010</a>; <a href="./references#CD009120-bbs2-0008" title="FavazzaA , MotanaroD , MessaP , AntonucciF , GropuzzoM , MioniG . Peritoneal clearances in hypertensive CAPD patients after oral administration of clonidine, enalapril, and nifedipine. Peritoneal Dialysis International1992;12(3):287‐91. [MEDLINE: 1511045] ">Favazza 1992</a>; <a href="./references#CD009120-bbs2-0009" title="HuangYH . Effect of angiotensin‐converting enzyme inhibitors on serum levels of erythropoietin in patients on peritoneal dialysis. Di Yi Junyi Daxue Xuebao2002;22(1):74‐5. [MEDLINE: 12390854] ">Huang 2002</a>; <a href="./references#CD009120-bbs2-0010" title="KolesnykI , NoordzijM , DekkerFW , BoeschotenEW , KredietRT . Treatment with angiotensin II inhibitors and residual renal function in peritoneal dialysis patients. Peritoneal Dialysis International2011;31(1):53‐9. [MEDLINE: 20522672] ">Kolesnyk 2011</a>; <a href="./references#CD009120-bbs2-0011" title="NakamotoH , KannoY , OkadaH , SuzukiH . Erythropoietin resistance in patients on continuous ambulatory peritoneal dialysis. Advances in Peritoneal Dialysis2004;20:111‐6. [MEDLINE: 15384808] ">Nakamoto 2004</a>; <a href="./references#CD009120-bbs2-0012" title="CollinsJF , RobsonR , MacMahonS , BaileyRR , PERFECT Study Group. Safety and efficacy of enalapril and simvastatin in dialysis patients [abstract]. 6th Asian Pacific Congress of Nephrology; 1995 Dec 5‐9; Hong Kong. 1995:144. [CENTRAL: CN‐00460572] RobsonR , CollinsJ , JohnsonR , KitchingR , SearleM , WalkerR , et al. Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis. The Perfect Study Collaborative Group. Journal of Nephrology1997;10(1):33‐40. [MEDLINE: 9241623] RobsonR , CollinsJ , KitchingsR , SearleM , WalkerR , SharpeN , et al. A randomized controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]. Journal of the American Society of Nephrology1994;5(3):526. [CENTRAL: CN‐00550525] RobsonRA , CollinsJ , WalkerRJ , MacMahonS . A randomised controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid, Spain. 1995:530. [CENTRAL: CN‐00509440] WalkerRJ , SutherlandWH , WalkerH . Simvastatin and cholesteryl ester transfer (CET) activity in renal failure (RF) [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid, Spain. 1995:529. [CENTRAL: CN‐00509553] WalkerRJ , SutherlandWH , WalkerH , RobsonRA , MacMahonSA . The effects of simvastatin and enalapril on plasma cholesteryl ester transfer (CET) activity in renal failure (RF) [abstract]. 6th Asian Pacific Congress of Nephrology; 1995 Dec 5‐9; Hong Kong. 1995:28. [CENTRAL: CN‐00461958] WalkerRJ , SutherlandWH , WalkerHL , MacMahonS , RobsonRA . Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. PERFECT Study Collaborative Group. Nephrology Dialysis Transplantation1997;12(1):87‐92. [MEDLINE: 9027779] ">PERFECT Study 1997</a>; <a href="./references#CD009120-bbs2-0013" title="Rojas‐CamposE , Cortes‐SanabriaL , Martinez‐RamirezHR , GonzalezL , Martin‐del‐CampoF , Gonzalez‐OrtizM , et al. Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. Peritoneal Dialysis International2005;25(6):576‐82. [MEDLINE: 16411525] Rojas‐CamposE , Martinez‐RamirezH , Cortes‐SanabriaL , CamachoR , Martin‐del‐CampoF , Cueto‐ManzanoAM . Oral verapamil increases ultrafiltration and peritoneal small solute clearance of CAPD patients [abstract no: SA‐FC130]. Journal of the American Society of Nephrology2005;16:110A. [CENTRAL: CN‐00583927] ">Rojas‐Campos 2005</a>; <a href="./references#CD009120-bbs2-0014" title="ShigenagaA , TamuraK , DejimaT , OzawaM , WakuiH , MasudaS , et al. Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis. Nephron Clinical Practice2009;112(1):c31–c40. [MEDLINE: 19342867] ">Shigenaga 2009</a>; <a href="./references#CD009120-bbs2-0015" title="SuzukiH , NakamotoH , OkadaH , SugaharaS , KannoY . A selective angiotensin receptor antagonist, valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness. Advances in Peritoneal Dialysis2003;19:59‐66. [MEDLINE: 14763035] ">Suzuki 2003</a>). A flow chart for our study selection procedure is presented as <a href="#CD009120-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD009120-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009120-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD009120-sec-0056"> <h4 class="title">Included studies</h4> <p>Three studies investigated the influence of an ARB on residual kidney function in CAPD patients (<a href="./references#CD009120-bbs2-0004" title="SuzukiH , KannoY , SugaharaS . Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. American Journal of Kidney Diseases2004;43(6):1056‐64. [MEDLINE: 15168386] ">Suzuki 2004;</a><a href="./references#CD009120-bbs2-0005" title="WangJ , XiaoMY . Protective effects of valsartan on residual renal function in patients on CAPD. Chinese Journal of Blood Purification2005;4(11):605‐6. ">Wang 2005d</a>; <a href="./references#CD009120-bbs2-0006" title="ZhongH , ShaCH , SuiTL , QiuHY , LiuF , QinW , et al. Effects of irbesartan on residual renal function in peritoneal dialysis patients. Chinese Journal of Nephrology2007;23(7):413‐6. ">Zhong 2007a</a>). Based on prospective calculation of sample size, <a href="./references#CD009120-bbs2-0004" title="SuzukiH , KannoY , SugaharaS . Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. American Journal of Kidney Diseases2004;43(6):1056‐64. [MEDLINE: 15168386] ">Suzuki 2004</a> enrolled 34 patients (male/female: 21/13; mean age: 63.5 years) and compared the effects of valsartan (40 to 80 mg/d) with other antihypertensive drugs (except an ACEi or an ARB). An antihypertensive regimen was proposed to achieve the target blood pressure (BP) of 130/80 mm Hg. Patients used 1.5 to 2.5 L of 2.5% dextrose dialysate/exchange for 3 to 5 exchanges/d for CAPD. <a href="./references#CD009120-bbs2-0006" title="ZhongH , ShaCH , SuiTL , QiuHY , LiuF , QinW , et al. Effects of irbesartan on residual renal function in peritoneal dialysis patients. Chinese Journal of Nephrology2007;23(7):413‐6. ">Zhong 2007a</a> enrolled 48 patients (male/female: 31/17; mean age: 44 years) and compared the effects of irbesartan (300 mg/d) with other antihypertensive drugs (except an ACEi or an ARB). An antihypertensive regimen was proposed to achieve the target BP of 12070 to 135/85 mm Hg. It was reported 1.5% or 2.5% dextrose dialysate was used, but detailed CAPD schedule was not available. In <a href="./references#CD009120-bbs2-0005" title="WangJ , XiaoMY . Protective effects of valsartan on residual renal function in patients on CAPD. Chinese Journal of Blood Purification2005;4(11):605‐6. ">Wang 2005d</a>, valsartan (40 to 80 mg/d) and other antihypertensive drugs were compared in 32 patients (male/female: 21/11; mean age: 42 years). Target BP was set at 130/80 mm Hg. Detailed CAPD schedule was not available. </p> <p><a href="./references#CD009120-bbs2-0001" title="LiPK , ChowK , WongTY , LeungC , SzetoCC . Effects of an angiotensin‐converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Annals of Internal Medicine2003;139(2):105‐12. [MEDLINE: 12859160] LiPK , ChowK , WongTY , LeungC , SzetoCC . Preservation of residual renal function in peritoneal dialysis patients by angiotensin‐converting‐enzyme inhibitor ‐ a prospective study [abstract no: F‐FC004]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):1a. [CENTRAL: CN‐00446373] ">Li 2003</a> assessed changes in residual kidney function in CAPD patients treated with the ACEi, ramipril (5 mg/d). On the basis of sample size estimation, 60 patients were included (male/female: 38/22; mean age: 58.6 years). Antihypertensive drugs other than an ACEi were allowed in both study and control groups to maintain target BP of 135/85 mm Hg. CAPD protocol was not provided. </p> <p>Two studies compared an ARB with an ACEi for preservation of residual kidney function in PD patients (<a href="./references#CD009120-bbs2-0002" title="PhakdeekitcharoenB , Leelasa‐nguanP . Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. American Journal of Kidney Diseases2004;44(4):738‐46. [MEDLINE: 15384026] ">Phakdeekitcharoen 2004</a>; <a href="./references#CD009120-bbs2-0003" title="Reyes‐MarinFA , CalzadaC , BallesterosA , AmatoD . Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study. Revista de Investigacion Clinica2012;64(4):315‐21. [MEDLINE: 23227581] ">Reyes‐Marin 2012</a>). <a href="./references#CD009120-bbs2-0002" title="PhakdeekitcharoenB , Leelasa‐nguanP . Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. American Journal of Kidney Diseases2004;44(4):738‐46. [MEDLINE: 15384026] ">Phakdeekitcharoen 2004</a> was a cross‐over study, which enrolled 21 patients (male/female: 14/7; mean age: 44.8 years) and compared the effects of candesartan (8 mg/d) with enalapril (10 mg/d) for four weeks (short‐term use). <a href="./references#CD009120-bbs2-0003" title="Reyes‐MarinFA , CalzadaC , BallesterosA , AmatoD . Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study. Revista de Investigacion Clinica2012;64(4):315‐21. [MEDLINE: 23227581] ">Reyes‐Marin 2012</a> enrolled 60 patients (male/female: 36/24) and compared the effects of losartan (50 mg/d) with enalapril (50 mg/d) for 12 months (long‐term use). Target BP was set at 130/85 mm Hg. </p> <p>See <a href="./references#CD009120-sec-0102" title="">Characteristics of included studies</a>. </p> </section> <section id="CD009120-sec-0057"> <h4 class="title">Excluded studies</h4> <p>Of the 18 studies (26 reports) identified, nine studies (16 reports) were excluded. One study was not randomised (<a href="./references#CD009120-bbs2-0010" title="KolesnykI , NoordzijM , DekkerFW , BoeschotenEW , KredietRT . Treatment with angiotensin II inhibitors and residual renal function in peritoneal dialysis patients. Peritoneal Dialysis International2011;31(1):53‐9. [MEDLINE: 20522672] ">Kolesnyk 2011</a>); one study enrolled ineligible patients (not all PD patients) (<a href="./references#CD009120-bbs2-0012" title="CollinsJF , RobsonR , MacMahonS , BaileyRR , PERFECT Study Group. Safety and efficacy of enalapril and simvastatin in dialysis patients [abstract]. 6th Asian Pacific Congress of Nephrology; 1995 Dec 5‐9; Hong Kong. 1995:144. [CENTRAL: CN‐00460572] RobsonR , CollinsJ , JohnsonR , KitchingR , SearleM , WalkerR , et al. Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis. The Perfect Study Collaborative Group. Journal of Nephrology1997;10(1):33‐40. [MEDLINE: 9241623] RobsonR , CollinsJ , KitchingsR , SearleM , WalkerR , SharpeN , et al. A randomized controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]. Journal of the American Society of Nephrology1994;5(3):526. [CENTRAL: CN‐00550525] RobsonRA , CollinsJ , WalkerRJ , MacMahonS . A randomised controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid, Spain. 1995:530. [CENTRAL: CN‐00509440] WalkerRJ , SutherlandWH , WalkerH . Simvastatin and cholesteryl ester transfer (CET) activity in renal failure (RF) [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid, Spain. 1995:529. [CENTRAL: CN‐00509553] WalkerRJ , SutherlandWH , WalkerH , RobsonRA , MacMahonSA . The effects of simvastatin and enalapril on plasma cholesteryl ester transfer (CET) activity in renal failure (RF) [abstract]. 6th Asian Pacific Congress of Nephrology; 1995 Dec 5‐9; Hong Kong. 1995:28. [CENTRAL: CN‐00461958] WalkerRJ , SutherlandWH , WalkerHL , MacMahonS , RobsonRA . Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. PERFECT Study Collaborative Group. Nephrology Dialysis Transplantation1997;12(1):87‐92. [MEDLINE: 9027779] ">PERFECT Study 1997</a>), and seven studies provided no information about residual kidney function (<a href="./references#CD009120-bbs2-0007" title="CioniA , SordiniC , CavalliniI , BigazziR , VitoM , CampeseVM . Angiotensin receptor blocker telmisartan improves insulin sensitivity in peritoneal dialysis patients. Peritoneal Dialysis International2010;30(1):66‐71. [MEDLINE: 20056982] ">Cioni 2010</a>; <a href="./references#CD009120-bbs2-0009" title="HuangYH . Effect of angiotensin‐converting enzyme inhibitors on serum levels of erythropoietin in patients on peritoneal dialysis. Di Yi Junyi Daxue Xuebao2002;22(1):74‐5. [MEDLINE: 12390854] ">Huang 2002</a>; <a href="./references#CD009120-bbs2-0011" title="NakamotoH , KannoY , OkadaH , SuzukiH . Erythropoietin resistance in patients on continuous ambulatory peritoneal dialysis. Advances in Peritoneal Dialysis2004;20:111‐6. [MEDLINE: 15384808] ">Nakamoto 2004</a>; <a href="./references#CD009120-bbs2-0014" title="ShigenagaA , TamuraK , DejimaT , OzawaM , WakuiH , MasudaS , et al. Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis. Nephron Clinical Practice2009;112(1):c31–c40. [MEDLINE: 19342867] ">Shigenaga 2009</a>; <a href="./references#CD009120-bbs2-0015" title="SuzukiH , NakamotoH , OkadaH , SugaharaS , KannoY . A selective angiotensin receptor antagonist, valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness. Advances in Peritoneal Dialysis2003;19:59‐66. [MEDLINE: 14763035] ">Suzuki 2003</a>; <a href="./references#CD009120-bbs2-0008" title="FavazzaA , MotanaroD , MessaP , AntonucciF , GropuzzoM , MioniG . Peritoneal clearances in hypertensive CAPD patients after oral administration of clonidine, enalapril, and nifedipine. Peritoneal Dialysis International1992;12(3):287‐91. [MEDLINE: 1511045] ">Favazza 1992</a>; <a href="./references#CD009120-bbs2-0013" title="Rojas‐CamposE , Cortes‐SanabriaL , Martinez‐RamirezHR , GonzalezL , Martin‐del‐CampoF , Gonzalez‐OrtizM , et al. Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. Peritoneal Dialysis International2005;25(6):576‐82. [MEDLINE: 16411525] Rojas‐CamposE , Martinez‐RamirezH , Cortes‐SanabriaL , CamachoR , Martin‐del‐CampoF , Cueto‐ManzanoAM . Oral verapamil increases ultrafiltration and peritoneal small solute clearance of CAPD patients [abstract no: SA‐FC130]. Journal of the American Society of Nephrology2005;16:110A. [CENTRAL: CN‐00583927] ">Rojas‐Campos 2005</a>). See <a href="./references#CD009120-sec-0103" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD009120-sec-0058"> <h3 class="title">Risk of bias in included studies</h3> <p>Details of the assessment of risk of bias of included studies are presented in <a href="#CD009120-fig-0002">Figure 2</a> and <a href="#CD009120-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD009120-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009120-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD009120-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009120-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009120-sec-0059"> <h4 class="title">Allocation</h4> <p>Two studies provided detailed allocation list generation methods (computer generated) and applied adequate allocation concealment (<a href="./references#CD009120-bbs2-0001" title="LiPK , ChowK , WongTY , LeungC , SzetoCC . Effects of an angiotensin‐converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Annals of Internal Medicine2003;139(2):105‐12. [MEDLINE: 12859160] LiPK , ChowK , WongTY , LeungC , SzetoCC . Preservation of residual renal function in peritoneal dialysis patients by angiotensin‐converting‐enzyme inhibitor ‐ a prospective study [abstract no: F‐FC004]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):1a. [CENTRAL: CN‐00446373] ">Li 2003</a>; <a href="./references#CD009120-bbs2-0004" title="SuzukiH , KannoY , SugaharaS . Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. American Journal of Kidney Diseases2004;43(6):1056‐64. [MEDLINE: 15168386] ">Suzuki 2004</a>), the remaining four studies did not provide details of allocation (<a href="./references#CD009120-bbs2-0002" title="PhakdeekitcharoenB , Leelasa‐nguanP . Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. American Journal of Kidney Diseases2004;44(4):738‐46. [MEDLINE: 15384026] ">Phakdeekitcharoen 2004</a>; <a href="./references#CD009120-bbs2-0003" title="Reyes‐MarinFA , CalzadaC , BallesterosA , AmatoD . Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study. Revista de Investigacion Clinica2012;64(4):315‐21. [MEDLINE: 23227581] ">Reyes‐Marin 2012</a>; <a href="./references#CD009120-bbs2-0005" title="WangJ , XiaoMY . Protective effects of valsartan on residual renal function in patients on CAPD. Chinese Journal of Blood Purification2005;4(11):605‐6. ">Wang 2005d</a>; <a href="./references#CD009120-bbs2-0006" title="ZhongH , ShaCH , SuiTL , QiuHY , LiuF , QinW , et al. Effects of irbesartan on residual renal function in peritoneal dialysis patients. Chinese Journal of Nephrology2007;23(7):413‐6. ">Zhong 2007a</a>). The methods used in the studies by <a href="./references#CD009120-bbs2-0005" title="WangJ , XiaoMY . Protective effects of valsartan on residual renal function in patients on CAPD. Chinese Journal of Blood Purification2005;4(11):605‐6. ">Wang 2005d</a> and <a href="./references#CD009120-bbs2-0006" title="ZhongH , ShaCH , SuiTL , QiuHY , LiuF , QinW , et al. Effects of irbesartan on residual renal function in peritoneal dialysis patients. Chinese Journal of Nephrology2007;23(7):413‐6. ">Zhong 2007a</a> were obtained through corresponding with the original authors. They used computer software to generate the sequence, but allocation concealment was not used. </p> </section> <section id="CD009120-sec-0060"> <h4 class="title">Blinding</h4> <p>One study did not provide any information about blinding (<a href="./references#CD009120-bbs2-0003" title="Reyes‐MarinFA , CalzadaC , BallesterosA , AmatoD . Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study. Revista de Investigacion Clinica2012;64(4):315‐21. [MEDLINE: 23227581] ">Reyes‐Marin 2012</a>), while the other five studies were open‐label. The primary outcome (residual kidney function) assessed in the review was obtained from laboratory tests, and it was judged as unlikely to be influenced by the status of blinding. BP measurements in four studies (<a href="./references#CD009120-bbs2-0004" title="SuzukiH , KannoY , SugaharaS . Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. American Journal of Kidney Diseases2004;43(6):1056‐64. [MEDLINE: 15168386] ">Suzuki 2004</a>; <a href="./references#CD009120-bbs2-0002" title="PhakdeekitcharoenB , Leelasa‐nguanP . Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. American Journal of Kidney Diseases2004;44(4):738‐46. [MEDLINE: 15384026] ">Phakdeekitcharoen 2004</a>; <a href="./references#CD009120-bbs2-0005" title="WangJ , XiaoMY . Protective effects of valsartan on residual renal function in patients on CAPD. Chinese Journal of Blood Purification2005;4(11):605‐6. ">Wang 2005d</a>; <a href="./references#CD009120-bbs2-0006" title="ZhongH , ShaCH , SuiTL , QiuHY , LiuF , QinW , et al. Effects of irbesartan on residual renal function in peritoneal dialysis patients. Chinese Journal of Nephrology2007;23(7):413‐6. ">Zhong 2007a</a>) however might be influenced. </p> </section> <section id="CD009120-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD009120-bbs2-0004" title="SuzukiH , KannoY , SugaharaS . Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. American Journal of Kidney Diseases2004;43(6):1056‐64. [MEDLINE: 15168386] ">Suzuki 2004</a> and <a href="./references#CD009120-bbs2-0003" title="Reyes‐MarinFA , CalzadaC , BallesterosA , AmatoD . Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study. Revista de Investigacion Clinica2012;64(4):315‐21. [MEDLINE: 23227581] ">Reyes‐Marin 2012</a> did not report detailed information of patients lost to follow‐up. In <a href="./references#CD009120-bbs2-0006" title="ZhongH , ShaCH , SuiTL , QiuHY , LiuF , QinW , et al. Effects of irbesartan on residual renal function in peritoneal dialysis patients. Chinese Journal of Nephrology2007;23(7):413‐6. ">Zhong 2007a</a>, two patients withdrew from the study, and two patients were lost to follow‐up with no reason identified. <a href="./references#CD009120-bbs2-0005" title="WangJ , XiaoMY . Protective effects of valsartan on residual renal function in patients on CAPD. Chinese Journal of Blood Purification2005;4(11):605‐6. ">Wang 2005d</a> reported that two patients withdrew from the study but reasons were not provided. In <a href="./references#CD009120-bbs2-0001" title="LiPK , ChowK , WongTY , LeungC , SzetoCC . Effects of an angiotensin‐converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Annals of Internal Medicine2003;139(2):105‐12. [MEDLINE: 12859160] LiPK , ChowK , WongTY , LeungC , SzetoCC . Preservation of residual renal function in peritoneal dialysis patients by angiotensin‐converting‐enzyme inhibitor ‐ a prospective study [abstract no: F‐FC004]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):1a. [CENTRAL: CN‐00446373] ">Li 2003</a>, five deaths occurred and 2 patients withdrew due to kidney transplantation; but it was noteworthy that five patients in the ACEi group discontinued ramipril due to persistent dizziness or cough, which are common side effects of ACEis. In <a href="./references#CD009120-bbs2-0002" title="PhakdeekitcharoenB , Leelasa‐nguanP . Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. American Journal of Kidney Diseases2004;44(4):738‐46. [MEDLINE: 15384026] ">Phakdeekitcharoen 2004</a>, eight patients (27.6%) withdraw and reasons were provided. </p> </section> <section id="CD009120-sec-0062"> <h4 class="title">Selective reporting</h4> <p>None of the included studies reported details of the study protocols or prespecified outcomes. There were insufficient data available to enable an assessment of selective reporting to be made. </p> </section> <section id="CD009120-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <p>Two studies did not provide detailed antihypertensive protocols (other than ACEis and ARBs) (<a href="./references#CD009120-bbs2-0005" title="WangJ , XiaoMY . Protective effects of valsartan on residual renal function in patients on CAPD. Chinese Journal of Blood Purification2005;4(11):605‐6. ">Wang 2005d</a>; <a href="./references#CD009120-bbs2-0006" title="ZhongH , ShaCH , SuiTL , QiuHY , LiuF , QinW , et al. Effects of irbesartan on residual renal function in peritoneal dialysis patients. Chinese Journal of Nephrology2007;23(7):413‐6. ">Zhong 2007a</a>), and PD schedules were not provided by four studies (<a href="./references#CD009120-bbs2-0001" title="LiPK , ChowK , WongTY , LeungC , SzetoCC . Effects of an angiotensin‐converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Annals of Internal Medicine2003;139(2):105‐12. [MEDLINE: 12859160] LiPK , ChowK , WongTY , LeungC , SzetoCC . Preservation of residual renal function in peritoneal dialysis patients by angiotensin‐converting‐enzyme inhibitor ‐ a prospective study [abstract no: F‐FC004]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):1a. [CENTRAL: CN‐00446373] ">Li 2003</a>; <a href="./references#CD009120-bbs2-0003" title="Reyes‐MarinFA , CalzadaC , BallesterosA , AmatoD . Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study. Revista de Investigacion Clinica2012;64(4):315‐21. [MEDLINE: 23227581] ">Reyes‐Marin 2012</a>; <a href="./references#CD009120-bbs2-0005" title="WangJ , XiaoMY . Protective effects of valsartan on residual renal function in patients on CAPD. Chinese Journal of Blood Purification2005;4(11):605‐6. ">Wang 2005d</a>; <a href="./references#CD009120-bbs2-0006" title="ZhongH , ShaCH , SuiTL , QiuHY , LiuF , QinW , et al. Effects of irbesartan on residual renal function in peritoneal dialysis patients. Chinese Journal of Nephrology2007;23(7):413‐6. ">Zhong 2007a</a>). </p> </section> </section> <section id="CD009120-sec-0064"> <h3 class="title" id="CD009120-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD009120-tbl-0001"><b>Summary of findings for the main comparison</b> Angiotensin receptor blockers (ARBs) versus conventional therapy for preserving residual kidney function in peritoneal dialysis patients</a>; <a href="./full#CD009120-tbl-0002"><b>Summary of findings 2</b> Angiotensin‐converting enzyme inhibitors (ACEi) versus conventional therapy for preserving residual kidney function in peritoneal dialysis patients</a>; <a href="./full#CD009120-tbl-0003"><b>Summary of findings 3</b> Angiotensin receptor blockers (ARBs) versus angiotensin‐converting enzyme inhibitors (ACEis) for preserving residual kidney function in peritoneal dialysis patients</a> </p> <section id="CD009120-sec-0065"> <h4 class="title">Residual kidney function</h4> <p>Three studies reported the effect of ARBs versus other antihypertensive drugs on residual kidney function at various time points. <a href="./references#CD009120-bbs2-0006" title="ZhongH , ShaCH , SuiTL , QiuHY , LiuF , QinW , et al. Effects of irbesartan on residual renal function in peritoneal dialysis patients. Chinese Journal of Nephrology2007;23(7):413‐6. ">Zhong 2007a</a> reported no significant difference between ARBs and other antihypertensive therapies in reducing the decline of residual kidney function at three months (<a href="./references#CD009120-fig-0004" title="">Analysis 1.1</a>.1 (1 study, 44 participants): MD ‐0.44 mL/min/1.73m², 95% CI ‐1.53 to 0.65) or six months (<a href="./references#CD009120-fig-0004" title="">Analysis 1.1</a>.2 (1 study, 44 participants): MD ‐0.20 mL/min/1.73 m², 95%CI ‐1.01 to 0.61); however ARBs significantly reduced the decline of residual kidney function at 12 months (<a href="./references#CD009120-fig-0004" title="">Analysis 1.1</a>.3 (1 study, 44 participants): MD 0.64 mL/min/1.73 m², 95% CI 0.19 to 1.09). At 24 months ARBs significantly reduced the decline in residual kidney function compared to other antihypertensive regimens (<a href="./references#CD009120-fig-0004" title="">Analysis 1.1</a>.4 (2 studies; 66 participants): MD 1.49 mL/min/1.73 m², 95% CI 1.12 to 1.86; I² = 0%). Long‐term use (≥ 12 months) of ARBs can benefit residual kidney function in PD patients (<a href="./references#CD009120-fig-0006" title="">Analysis 1.3</a> MD 1.11 mL/min/1.73 m², 95% CI 0.38 to 1.83). </p> <p><a href="./references#CD009120-bbs2-0001" title="LiPK , ChowK , WongTY , LeungC , SzetoCC . Effects of an angiotensin‐converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Annals of Internal Medicine2003;139(2):105‐12. [MEDLINE: 12859160] LiPK , ChowK , WongTY , LeungC , SzetoCC . Preservation of residual renal function in peritoneal dialysis patients by angiotensin‐converting‐enzyme inhibitor ‐ a prospective study [abstract no: F‐FC004]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):1a. [CENTRAL: CN‐00446373] ">Li 2003</a> reported over 12 months ACEis significantly reduced the decline of residual kidney function compared with other antihypertensive drugs (<a href="./references#CD009120-fig-0012" title="">Analysis 2.1</a> (1 study, 60 participants): MD ‐0.93 mL/min/1.73 m², 95% CI ‐1.75 to ‐0.11). </p> <p><a href="./references#CD009120-bbs2-0002" title="PhakdeekitcharoenB , Leelasa‐nguanP . Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. American Journal of Kidney Diseases2004;44(4):738‐46. [MEDLINE: 15384026] ">Phakdeekitcharoen 2004</a> and <a href="./references#CD009120-bbs2-0003" title="Reyes‐MarinFA , CalzadaC , BallesterosA , AmatoD . Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study. Revista de Investigacion Clinica2012;64(4):315‐21. [MEDLINE: 23227581] ">Reyes‐Marin 2012</a> reported no significant differences in residual kidney function preservation between ARBs and ACEis in short‐term (four weeks) (<a href="./references#CD009120-fig-0017" title="">Analysis 3.1</a>.1 (1 study, 20 participants): MD ‐0.47 mL/min/1.73 m², 95% CI ‐2.73 to 1.79) or long‐term use (12 months) (<a href="./references#CD009120-fig-0019" title="">Analysis 3.3</a> (1 study, 60 participants): MD 0.18 mL/min/1.73 m², 95% CI ‐0.04 to 0.40). </p> </section> <section id="CD009120-sec-0066"> <h4 class="title">All‐cause mortality</h4> <p>Mortality was not reported in the studies comparing ACEis with other antihypertensive drugs or studies comparing ARBs with ACEis. </p> <p><a href="./references#CD009120-bbs2-0001" title="LiPK , ChowK , WongTY , LeungC , SzetoCC . Effects of an angiotensin‐converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Annals of Internal Medicine2003;139(2):105‐12. [MEDLINE: 12859160] LiPK , ChowK , WongTY , LeungC , SzetoCC . Preservation of residual renal function in peritoneal dialysis patients by angiotensin‐converting‐enzyme inhibitor ‐ a prospective study [abstract no: F‐FC004]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):1a. [CENTRAL: CN‐00446373] ">Li 2003</a> reported no significant difference in mortality between patients treated with ACEis compared with other antihypertensive drugs (<a href="./references#CD009120-fig-0013" title="">Analysis 2.2</a> (1 study, 60 patients): RR 1.50, 95% CI 0.27 to 8.34). </p> </section> <section id="CD009120-sec-0067"> <h4 class="title">Cardiovascular events</h4> <section id="CD009120-sec-0068"> <h5 class="title">ARBs versus other antihypertensive drugs</h5> <p>Cardiovascular events were not reported in the studies comparing an ARB with other antihypertensive drugs. </p> <p><a href="./references#CD009120-bbs2-0001" title="LiPK , ChowK , WongTY , LeungC , SzetoCC . Effects of an angiotensin‐converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Annals of Internal Medicine2003;139(2):105‐12. [MEDLINE: 12859160] LiPK , ChowK , WongTY , LeungC , SzetoCC . Preservation of residual renal function in peritoneal dialysis patients by angiotensin‐converting‐enzyme inhibitor ‐ a prospective study [abstract no: F‐FC004]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):1a. [CENTRAL: CN‐00446373] ">Li 2003</a> reported no significant differences between ACEis and other antihypertensive drugs for both fatal (<a href="./references#CD009120-fig-0014" title="">Analysis 2.3</a>.1 (1 study, 60 participants): RR 1.00, 95% CI 0.15 to 6.64) and non‐fatal (<a href="./references#CD009120-fig-0014" title="">Analysis 2.3</a>.2 (1 study, 60 patients): RR 1.00, 95% CI 0.22 to 4.56) cardiovascular events. </p> <p><a href="./references#CD009120-bbs2-0003" title="Reyes‐MarinFA , CalzadaC , BallesterosA , AmatoD . Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study. Revista de Investigacion Clinica2012;64(4):315‐21. [MEDLINE: 23227581] ">Reyes‐Marin 2012</a> reported no fatal cardiovascular events occurred in either the ARB or ACEi groups, and no significant difference for non‐fatal cardiovascular events (<a href="./references#CD009120-fig-0018" title="">Analysis 3.2</a> (1 study, 60 participants): RR 1.38, 95% CI 0.28 to 6.80). </p> </section> </section> <section id="CD009120-sec-0069"> <h4 class="title">Urinary protein excretion</h4> <p>There was no significant difference in urinary protein excretion between patients treated with ARBs and those treated with other antihypertensive drugs (<a href="./references#CD009120-fig-0005" title="">Analysis 1.2</a> (2 studies, 66 patients): MD ‐0.01 g/d, 95% CI ‐0.09 to 0.06). </p> <p>Urinary protein excretion was not reported in the studies comparing an ACEi with other antihypertensive drugs or studies comparing an ARB with an ACEi. </p> </section> <section id="CD009120-sec-0070"> <h4 class="title">Anuria</h4> <p>Anuria was not reported in the studies comparing an ARB with other antihypertensive drugs. </p> <p><a href="./references#CD009120-bbs2-0001" title="LiPK , ChowK , WongTY , LeungC , SzetoCC . Effects of an angiotensin‐converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Annals of Internal Medicine2003;139(2):105‐12. [MEDLINE: 12859160] LiPK , ChowK , WongTY , LeungC , SzetoCC . Preservation of residual renal function in peritoneal dialysis patients by angiotensin‐converting‐enzyme inhibitor ‐ a prospective study [abstract no: F‐FC004]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):1a. [CENTRAL: CN‐00446373] ">Li 2003</a> reported over 12 months ACEis significantly reduced the number progression to complete anuria compared to other antihypertensive drugs (<a href="./references#CD009120-fig-0015" title="">Analysis 2.4</a> (1 study, 60 participants): RR 0.32, 95% CI 0.11 to 0.94). </p> <p><a href="./references#CD009120-bbs2-0003" title="Reyes‐MarinFA , CalzadaC , BallesterosA , AmatoD . Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study. Revista de Investigacion Clinica2012;64(4):315‐21. [MEDLINE: 23227581] ">Reyes‐Marin 2012</a> reported no significant difference in the progression to complete anuria between the ARB and ACEi groups (<a href="./references#CD009120-fig-0019" title="">Analysis 3.3</a> (1 study, 42 participants): RR 1.15, 95% CI 0.41 to 3.26). </p> </section> <section id="CD009120-sec-0071"> <h4 class="title">Dialysis adequacy</h4> <p>Dialysis adequacy was measured in studies comparing ARBs with other antihypertensive drugs. There was no significant difference in Kt/V between patients treated with ARBs and those treated with other antihypertensive drugs (<a href="./references#CD009120-fig-0006" title="">Analysis 1.3</a> (2 studies, 76 participants): MD 0.10, 95% CI ‐0.02 to 0.22). There was no significant difference in weekly creatinine clearance between patients treated with ARBs and those treated with other antihypertensive drugs (<a href="./references#CD009120-fig-0007" title="">Analysis 1.4</a> (3 studies, 110 participants): MD 9.06 mL/wk/1.73 m², 95% CI ‐2.77 to 20.90; I² = 76%), however significant heterogeneity was identified. </p> <p>Dialysis adequacy was not reported in studies comparing an ACEi with other antihypertensive drugs or studies comparing an ARB with an ACEi. </p> </section> <section id="CD009120-sec-0072"> <h4 class="title">Blood pressure</h4> <p>In studies comparing ARBs with other antihypertensive drugs there were no significant differences in either systolic blood pressure (<a href="./references#CD009120-fig-0008" title="">Analysis 1.5</a> (3 studies, 110 participants): MD ‐0.67 mm Hg, 95% CI ‐2.77 to 1.42; I² = 0%) or diastolic blood pressure (<a href="./references#CD009120-fig-0009" title="">Analysis 1.6</a> (3 studies, 110 participants): MD ‐0.70 mm Hg, 95% CI ‐2.14 to 0.74; I² = 0%). </p> <p><a href="./references#CD009120-bbs2-0003" title="Reyes‐MarinFA , CalzadaC , BallesterosA , AmatoD . Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study. Revista de Investigacion Clinica2012;64(4):315‐21. [MEDLINE: 23227581] ">Reyes‐Marin 2012</a> reported no significant differences between the ARB and ACEi groups for either systolic blood pressure (<a href="./references#CD009120-fig-0020" title="">Analysis 3.4</a> (1 study, 42 participants): MD 0.48 mm Hg, 95% CI ‐7.76 to 8.72) or diastolic blood pressure (<a href="./references#CD009120-fig-0021" title="">Analysis 3.5</a> (1 study, 42 participants): MD ‐0.38 mm Hg, 95% CI ‐6.76 to 7.52). </p> <p>Blood pressure was not reported in the studies comparing an ACEi with other antihypertensive drugs. </p> </section> <section id="CD009120-sec-0073"> <h4 class="title">Peritonitis</h4> <p><a href="./references#CD009120-bbs2-0004" title="SuzukiH , KannoY , SugaharaS . Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. American Journal of Kidney Diseases2004;43(6):1056‐64. [MEDLINE: 15168386] ">Suzuki 2004</a> reported no significant difference in the number of patients experiencing peritonitis between the ARB and other antihypertensive drug groups (<a href="./references#CD009120-fig-0010" title="">Analysis 1.7</a> (1 study, 34 participants): RR 0.67, 95% CI 0.18 to 2.54). </p> <p><a href="./references#CD009120-bbs2-0001" title="LiPK , ChowK , WongTY , LeungC , SzetoCC . Effects of an angiotensin‐converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Annals of Internal Medicine2003;139(2):105‐12. [MEDLINE: 12859160] LiPK , ChowK , WongTY , LeungC , SzetoCC . Preservation of residual renal function in peritoneal dialysis patients by angiotensin‐converting‐enzyme inhibitor ‐ a prospective study [abstract no: F‐FC004]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):1a. [CENTRAL: CN‐00446373] ">Li 2003</a> reported no significant difference in the number of patients experiencing peritonitis between the ACEi and control groups (<a href="./references#CD009120-fig-0016" title="">Analysis 2.5</a>.1 (1 study, 60 participants): RR 1.13, 95% CI 0.50 to 2.52). There was no significant difference between the groups for those either treated with an aminoglycoside (<a href="./references#CD009120-fig-0016" title="">Analysis 2.5</a>.2: RR 1.20, 95% CI 0.41 to 3.51) or not treated with an aminoglycoside (<a href="./references#CD009120-fig-0016" title="">Analysis 2.5</a>.3: RR 1.00, 95% CI 0.22 to 4.56). </p> <p><a href="./references#CD009120-bbs2-0003" title="Reyes‐MarinFA , CalzadaC , BallesterosA , AmatoD . Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study. Revista de Investigacion Clinica2012;64(4):315‐21. [MEDLINE: 23227581] ">Reyes‐Marin 2012</a> reported no significant difference in the number of patients experiencing peritonitis between the ARB and ACEi groups (<a href="./references#CD009120-fig-0022" title="">Analysis 3.6</a> (1 study, 60 patients): RR 1.17, 95% CI 0.44 to 3.06). </p> </section> <section id="CD009120-sec-0074"> <h4 class="title">Cough</h4> <p>Cough was not reported in the studies comparing an ARB or an ACEi with other antihypertensive drugs. </p> <p><a href="./references#CD009120-bbs2-0003" title="Reyes‐MarinFA , CalzadaC , BallesterosA , AmatoD . Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study. Revista de Investigacion Clinica2012;64(4):315‐21. [MEDLINE: 23227581] ">Reyes‐Marin 2012</a> reported no significant difference in the number of patients experiencing cough between the ARB and ACEi groups (<a href="./references#CD009120-fig-0023" title="">Analysis 3.7</a> (1 study, 60 patients): RR 1.50, 95% CI 0.27 to 8.34). </p> </section> <section id="CD009120-sec-0075"> <h4 class="title">Serum potassium</h4> <p><a href="./references#CD009120-bbs2-0006" title="ZhongH , ShaCH , SuiTL , QiuHY , LiuF , QinW , et al. Effects of irbesartan on residual renal function in peritoneal dialysis patients. Chinese Journal of Nephrology2007;23(7):413‐6. ">Zhong 2007a</a> reported no significant difference in serum potassium level between the ARB and other antihypertensive drug groups (<a href="./references#CD009120-fig-0011" title="">Analysis 1.8</a> (1 study, 44 participants): MD 0.13 mmol/L, 95% CI ‐0.12 to 0.38). </p> <p><a href="./references#CD009120-bbs2-0002" title="PhakdeekitcharoenB , Leelasa‐nguanP . Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. American Journal of Kidney Diseases2004;44(4):738‐46. [MEDLINE: 15384026] ">Phakdeekitcharoen 2004</a> reported no statistical difference was observed in serum potassium between the ARB and ACEi groups (<a href="./references#CD009120-fig-0024" title="">Analysis 3.8</a> (1 study, 42 participants): MD ‐0.05 mmol/L, 95% CI ‐0.45 to 0.35). </p> <p>Serum potassium was not reported in any of the studies comparing an ACEi with other antihypertensive drugs. </p> </section> <section id="CD009120-sec-0076"> <h4 class="title">Hyperkalaemia</h4> <p>Hyperkalaemia was not reported in studies comparing an ARB or an ACEi with other antihypertensive drugs. </p> <p>There was no significant difference in the number patients experiencing hyperkalaemia between the ARB and ACEi groups (<a href="./references#CD009120-fig-0025" title="">Analysis 3.9</a> (2 studies, 84 events): RR 1.20, 95% CI 0.40 to 3.63) </p> </section> <section id="CD009120-sec-0077"> <h4 class="title">Other outcomes</h4> <p>The following outcomes were not reported by any of the included studies: hypotension; angioedema; the number of patients changing from PD to HD; increasing PD dose due to declining of residual kidney function; or quality of life. </p> <p>Due to the small number of studies identified we were unable to perform subgroup analyses to investigate heterogeneity, perform sensitivity analyses, assess publication biases, or tabulate adverse events as stated in our protocol. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009120-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009120-sec-0078"></div> <section id="CD009120-sec-0079"> <h3 class="title" id="CD009120-sec-0079">Summary of main results</h3> <p>This review assessed six small RCTs enrolling 257 participants. Three studies compared an ARB with other antihypertensive drugs (<a href="./references#CD009120-bbs2-0004" title="SuzukiH , KannoY , SugaharaS . Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. American Journal of Kidney Diseases2004;43(6):1056‐64. [MEDLINE: 15168386] ">Suzuki 2004</a>; <a href="./references#CD009120-bbs2-0005" title="WangJ , XiaoMY . Protective effects of valsartan on residual renal function in patients on CAPD. Chinese Journal of Blood Purification2005;4(11):605‐6. ">Wang 2005d</a>; <a href="./references#CD009120-bbs2-0006" title="ZhongH , ShaCH , SuiTL , QiuHY , LiuF , QinW , et al. Effects of irbesartan on residual renal function in peritoneal dialysis patients. Chinese Journal of Nephrology2007;23(7):413‐6. ">Zhong 2007a</a>), one study compared an ACEi with other antihypertensive drugs (<a href="./references#CD009120-bbs2-0001" title="LiPK , ChowK , WongTY , LeungC , SzetoCC . Effects of an angiotensin‐converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Annals of Internal Medicine2003;139(2):105‐12. [MEDLINE: 12859160] LiPK , ChowK , WongTY , LeungC , SzetoCC . Preservation of residual renal function in peritoneal dialysis patients by angiotensin‐converting‐enzyme inhibitor ‐ a prospective study [abstract no: F‐FC004]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):1a. [CENTRAL: CN‐00446373] ">Li 2003</a>), and two studies compared an ARB with an ACEi (<a href="./references#CD009120-bbs2-0002" title="PhakdeekitcharoenB , Leelasa‐nguanP . Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. American Journal of Kidney Diseases2004;44(4):738‐46. [MEDLINE: 15384026] ">Phakdeekitcharoen 2004</a>; <a href="./references#CD009120-bbs2-0003" title="Reyes‐MarinFA , CalzadaC , BallesterosA , AmatoD . Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study. Revista de Investigacion Clinica2012;64(4):315‐21. [MEDLINE: 23227581] ">Reyes‐Marin 2012</a>). Long‐term use (≥ 12 months) of an ARB showed significant benefit in preserving residual kidney function in CAPD patients (MD 1.11 mL/min/1.73 m², 95% CI 0.38 to 1.83), although there was no significant benefit when an ARB were used short‐term (≤ 6 months). One study showed that compared with other antihypertensive drugs, long‐term use (12 months) of the ACEi ramipril, showed a significant reduction in the decline of residual kidney function in patients on CAPD (MD ‐0.93 mL/min/1.73 m², 95% CI ‐1.75 to ‐0.11), as well as slowing of the progression to complete anuria (RR 0.64, 95% CI 0.41 to 0.99). There was no significant difference in serum potassium levels, urinary protein excretion, Kt/V, weekly creatinine clearance and blood pressure for an ARB versus other antihypertensive drugs. Compared with other antihypertensive drugs, ramipril showed no difference in mortality and cardiovascular events. In two studies, there was no significant difference on residual kidney function preservation between an ARB and an ACEi in short‐ or long‐term use (4 weeks: MD ‐0.47 mL/min/1.73 m², 95% CI ‐2.73 to 1.79; 12 months: MD 0.18 mL/min/1.73 m², 95% CI ‐0.04 to 0.40). </p> </section> <section id="CD009120-sec-0080"> <h3 class="title" id="CD009120-sec-0080">Overall completeness and applicability of evidence</h3> <p>This systematic review presents clinical evidence of the application of an ACEi or an ARB for preserving residual kidney function in PD patients. However, the evidence provided in these six small RCTs is limited in their completeness and applicability. </p> <p>Firstly, the primary outcome we had planned to investigate were not adequately addressed in the included studies. The long‐term effect of an ACEi on residual kidney function was only reported in one study comparing with other antihypertensive drugs (<a href="./references#CD009120-bbs2-0001" title="LiPK , ChowK , WongTY , LeungC , SzetoCC . Effects of an angiotensin‐converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Annals of Internal Medicine2003;139(2):105‐12. [MEDLINE: 12859160] LiPK , ChowK , WongTY , LeungC , SzetoCC . Preservation of residual renal function in peritoneal dialysis patients by angiotensin‐converting‐enzyme inhibitor ‐ a prospective study [abstract no: F‐FC004]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):1a. [CENTRAL: CN‐00446373] ">Li 2003</a>). For short‐term effects on residual kidney function, only one study reported an ARB compared with other antihypertensive drugs (<a href="./references#CD009120-bbs2-0006" title="ZhongH , ShaCH , SuiTL , QiuHY , LiuF , QinW , et al. Effects of irbesartan on residual renal function in peritoneal dialysis patients. Chinese Journal of Nephrology2007;23(7):413‐6. ">Zhong 2007a</a>), and the data of short‐term effect of an ACEi on residual kidney function was lacking. In the two studies comparing an ARB with an ACEi, <a href="./references#CD009120-bbs2-0002" title="PhakdeekitcharoenB , Leelasa‐nguanP . Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. American Journal of Kidney Diseases2004;44(4):738‐46. [MEDLINE: 15384026] ">Phakdeekitcharoen 2004</a> was a cross‐over study of short‐term use (four weeks), and <a href="./references#CD009120-bbs2-0003" title="Reyes‐MarinFA , CalzadaC , BallesterosA , AmatoD . Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study. Revista de Investigacion Clinica2012;64(4):315‐21. [MEDLINE: 23227581] ">Reyes‐Marin 2012</a> did not provide any information about allocation and blinding. </p> <p>Secondly, no detailed analysis was provided addressing the divergence in age, sex, aetiologic factors and dosage of ACEis and ARBs. As a result, related subgroup analysis was not performed as planned. Adverse events such as hypotension and angioedema were not reported in any of the included studies. </p> <p>Thirdly, it was also noteworthy that four studies (<a href="./references#CD009120-bbs2-0001" title="LiPK , ChowK , WongTY , LeungC , SzetoCC . Effects of an angiotensin‐converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Annals of Internal Medicine2003;139(2):105‐12. [MEDLINE: 12859160] LiPK , ChowK , WongTY , LeungC , SzetoCC . Preservation of residual renal function in peritoneal dialysis patients by angiotensin‐converting‐enzyme inhibitor ‐ a prospective study [abstract no: F‐FC004]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):1a. [CENTRAL: CN‐00446373] ">Li 2003</a>; <a href="./references#CD009120-bbs2-0004" title="SuzukiH , KannoY , SugaharaS . Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. American Journal of Kidney Diseases2004;43(6):1056‐64. [MEDLINE: 15168386] ">Suzuki 2004</a>; <a href="./references#CD009120-bbs2-0005" title="WangJ , XiaoMY . Protective effects of valsartan on residual renal function in patients on CAPD. Chinese Journal of Blood Purification2005;4(11):605‐6. ">Wang 2005d</a>; <a href="./references#CD009120-bbs2-0006" title="ZhongH , ShaCH , SuiTL , QiuHY , LiuF , QinW , et al. Effects of irbesartan on residual renal function in peritoneal dialysis patients. Chinese Journal of Nephrology2007;23(7):413‐6. ">Zhong 2007a</a>), which compared an ARB or an ACEi with other antihypertensive drugs, all included Asian participants, limiting the applicability of the evidence presented by the review to other ethnic or racial groups. </p> </section> <section id="CD009120-sec-0081"> <h3 class="title" id="CD009120-sec-0081">Quality of the evidence</h3> <p>Of the six included RCTs, two provided detailed random sequence generation methods (computer generated) and applied adequate allocation concealment (<a href="./references#CD009120-bbs2-0001" title="LiPK , ChowK , WongTY , LeungC , SzetoCC . Effects of an angiotensin‐converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Annals of Internal Medicine2003;139(2):105‐12. [MEDLINE: 12859160] LiPK , ChowK , WongTY , LeungC , SzetoCC . Preservation of residual renal function in peritoneal dialysis patients by angiotensin‐converting‐enzyme inhibitor ‐ a prospective study [abstract no: F‐FC004]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):1a. [CENTRAL: CN‐00446373] ">Li 2003</a>; <a href="./references#CD009120-bbs2-0004" title="SuzukiH , KannoY , SugaharaS . Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. American Journal of Kidney Diseases2004;43(6):1056‐64. [MEDLINE: 15168386] ">Suzuki 2004</a>). In the other four studies, the allocation approach used by <a href="./references#CD009120-bbs2-0005" title="WangJ , XiaoMY . Protective effects of valsartan on residual renal function in patients on CAPD. Chinese Journal of Blood Purification2005;4(11):605‐6. ">Wang 2005d</a> and <a href="./references#CD009120-bbs2-0006" title="ZhongH , ShaCH , SuiTL , QiuHY , LiuF , QinW , et al. Effects of irbesartan on residual renal function in peritoneal dialysis patients. Chinese Journal of Nephrology2007;23(7):413‐6. ">Zhong 2007a</a> were obtained through corresponding with the original authors. They also used computer software to generate the sequence, but allocation concealment was not used. With the exception of <a href="./references#CD009120-bbs2-0003" title="Reyes‐MarinFA , CalzadaC , BallesterosA , AmatoD . Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study. Revista de Investigacion Clinica2012;64(4):315‐21. [MEDLINE: 23227581] ">Reyes‐Marin 2012</a> which did not provide any information about blinding, other five included studies were open‐label. However, our primary outcome (residual kidney function) were obtained from laboratory tests, and were not likely to be influenced by the blinding of the participants or investigators; BP measurements in four studies (<a href="./references#CD009120-bbs2-0004" title="SuzukiH , KannoY , SugaharaS . Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. American Journal of Kidney Diseases2004;43(6):1056‐64. [MEDLINE: 15168386] ">Suzuki 2004</a>; <a href="./references#CD009120-bbs2-0005" title="WangJ , XiaoMY . Protective effects of valsartan on residual renal function in patients on CAPD. Chinese Journal of Blood Purification2005;4(11):605‐6. ">Wang 2005d</a>; <a href="./references#CD009120-bbs2-0006" title="ZhongH , ShaCH , SuiTL , QiuHY , LiuF , QinW , et al. Effects of irbesartan on residual renal function in peritoneal dialysis patients. Chinese Journal of Nephrology2007;23(7):413‐6. ">Zhong 2007a</a>; <a href="./references#CD009120-bbs2-0002" title="PhakdeekitcharoenB , Leelasa‐nguanP . Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. American Journal of Kidney Diseases2004;44(4):738‐46. [MEDLINE: 15384026] ">Phakdeekitcharoen 2004</a>) might however be influenced. <a href="./references#CD009120-bbs2-0004" title="SuzukiH , KannoY , SugaharaS . Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. American Journal of Kidney Diseases2004;43(6):1056‐64. [MEDLINE: 15168386] ">Suzuki 2004</a> did not report detailed information of patients lost to follow‐up. In <a href="./references#CD009120-bbs2-0006" title="ZhongH , ShaCH , SuiTL , QiuHY , LiuF , QinW , et al. Effects of irbesartan on residual renal function in peritoneal dialysis patients. Chinese Journal of Nephrology2007;23(7):413‐6. ">Zhong 2007a</a>, two patients withdrew from the study, and two patients were lost to follow‐up with no reasons reported. In the study by <a href="./references#CD009120-bbs2-0005" title="WangJ , XiaoMY . Protective effects of valsartan on residual renal function in patients on CAPD. Chinese Journal of Blood Purification2005;4(11):605‐6. ">Wang 2005d</a>, two patients withdrew from the study, again with no reasons reported. In <a href="./references#CD009120-bbs2-0001" title="LiPK , ChowK , WongTY , LeungC , SzetoCC . Effects of an angiotensin‐converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Annals of Internal Medicine2003;139(2):105‐12. [MEDLINE: 12859160] LiPK , ChowK , WongTY , LeungC , SzetoCC . Preservation of residual renal function in peritoneal dialysis patients by angiotensin‐converting‐enzyme inhibitor ‐ a prospective study [abstract no: F‐FC004]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):1a. [CENTRAL: CN‐00446373] ">Li 2003</a>, five deaths occurred and two patients withdrew due to kidney transplantation; it was noteworthy that five patients in the ACEi group discontinued ramipril due to persistent dizziness or cough, which were common side effects of ACEis. In <a href="./references#CD009120-bbs2-0002" title="PhakdeekitcharoenB , Leelasa‐nguanP . Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. American Journal of Kidney Diseases2004;44(4):738‐46. [MEDLINE: 15384026] ">Phakdeekitcharoen 2004</a>, eight patients (27.6%) withdraw and the reasons were provided. Some parameters listed in the <a href="#CD009120-sec-0029">Methods</a> were not further addressed, but all included studies reported the primary outcome. Since study protocols were not available, it was difficult to determine whether there was high risk of selective reporting. </p> </section> <section id="CD009120-sec-0082"> <h3 class="title" id="CD009120-sec-0082">Potential biases in the review process</h3> <p>While we have made efforts to identify clinical studies relevant to our topic in electronic searches and clinical trial registers, we cannot deny the possibility that unpublished studies might exist. Since only four studies were included, we did not construct funnel plots to explore reporting biases. All of these studies did not have protocols available on public clinical trial registers, therefore we couldn't assess selective outcomes reporting. </p> </section> <section id="CD009120-sec-0083"> <h3 class="title" id="CD009120-sec-0083">Agreements and disagreements with other studies or reviews</h3> <p><a href="./references#CD009120-bbs2-0019" title="AkbariA , KnollG , FergusonD , McCormickB , DavisA , BiyaniM . Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers in peritoneal dialysis: systematic review and meta‐analysis of randomized controlled trials. Peritoneal Dialysis International2009;29(5):554–61. [MEDLINE: 19776050] ">Akbari 2009</a> evaluated the effects of ACEis and ARBs in PD, but included only two RCTs (<a href="./references#CD009120-bbs2-0001" title="LiPK , ChowK , WongTY , LeungC , SzetoCC . Effects of an angiotensin‐converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Annals of Internal Medicine2003;139(2):105‐12. [MEDLINE: 12859160] LiPK , ChowK , WongTY , LeungC , SzetoCC . Preservation of residual renal function in peritoneal dialysis patients by angiotensin‐converting‐enzyme inhibitor ‐ a prospective study [abstract no: F‐FC004]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):1a. [CENTRAL: CN‐00446373] ">Li 2003</a>; <a href="./references#CD009120-bbs2-0004" title="SuzukiH , KannoY , SugaharaS . Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. American Journal of Kidney Diseases2004;43(6):1056‐64. [MEDLINE: 15168386] ">Suzuki 2004</a>) to evaluate the effects of an ACEi and an ARB on residual kidney function. <a href="./references#CD009120-bbs2-0019" title="AkbariA , KnollG , FergusonD , McCormickB , DavisA , BiyaniM . Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers in peritoneal dialysis: systematic review and meta‐analysis of randomized controlled trials. Peritoneal Dialysis International2009;29(5):554–61. [MEDLINE: 19776050] ">Akbari 2009</a> reported residual kidney function at 12 months and the weighted MD was 0.91 mL/min/1.73 m² (95% CI 0.14 to 1.68), favouring the use of an ACEi and an ARB, which is similar to our study. However, the result of a recent study by <a href="./references#CD009120-bbs2-0010" title="KolesnykI , NoordzijM , DekkerFW , BoeschotenEW , KredietRT . Treatment with angiotensin II inhibitors and residual renal function in peritoneal dialysis patients. Peritoneal Dialysis International2011;31(1):53‐9. [MEDLINE: 20522672] ">Kolesnyk 2011</a> is not in line with the results of this review. This study is a large, prospective, multicentre cohort study including 451 Dutch participants, which showed that ACEis and ARBs had no additional benefit in preserving residual kidney function over three years of PD treatment (P = 0.52). However, details of changes of six, 12, 24, 36 months of residual kidney function were lacking. Some bias existed such as non‐randomised design, selection bias and attrition bias, which might influence the results of this study. A recent observational study indicated that the absence of an ACEi or an ARB was one of independent risk factors associated with rapidly declining residual kidney function (<a href="./references#CD009120-bbs2-0028" title="Herget‐RosenthalS , vonOstrowskiM , KribbenA . Definition and risk factors of rapidly declining residual renal function in peritoneal dialysis: an observational study. Kidney &amp; Blood Pressure Research2012;35(4):233‐41. [MEDLINE: 22223267] ">Herget‐Rosenthal 2012</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009120-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009120-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/full#CD009120-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009120-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009120-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/full#CD009120-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009120-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009120-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/full#CD009120-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009120-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ARBs versus other antihypertensive drugs, Outcome 1 Residual kidney function [mL/min/1.73 m²]." data-id="CD009120-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 ARBs versus other antihypertensive drugs, Outcome 1 Residual kidney function [mL/min/1.73 m²]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009120-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ARBs versus other antihypertensive drugs, Outcome 2 Urinary protein excretion." data-id="CD009120-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 ARBs versus other antihypertensive drugs, Outcome 2 Urinary protein excretion.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009120-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ARBs versus other antihypertensive drugs, Outcome 3 Kt/V." data-id="CD009120-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 ARBs versus other antihypertensive drugs, Outcome 3 Kt/V.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009120-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ARBs versus other antihypertensive drugs, Outcome 4 Weekly creatinine clearance [mL/wk/1.73 m²]." data-id="CD009120-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 ARBs versus other antihypertensive drugs, Outcome 4 Weekly creatinine clearance [mL/wk/1.73 m²]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009120-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ARBs versus other antihypertensive drugs, Outcome 5 Systolic BP." data-id="CD009120-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 ARBs versus other antihypertensive drugs, Outcome 5 Systolic BP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009120-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ARBs versus other antihypertensive drugs, Outcome 6 Diastolic BP." data-id="CD009120-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 ARBs versus other antihypertensive drugs, Outcome 6 Diastolic BP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009120-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ARBs versus other antihypertensive drugs, Outcome 7 Peritonitis." data-id="CD009120-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 ARBs versus other antihypertensive drugs, Outcome 7 Peritonitis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009120-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ARBs versus other antihypertensive drugs, Outcome 8 Serum potassium." data-id="CD009120-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 ARBs versus other antihypertensive drugs, Outcome 8 Serum potassium.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009120-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ACEis versus other antihypertensive drugs, Outcome 1 Change in residual kidney function [mL/min/1.73 m²]." data-id="CD009120-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 ACEis versus other antihypertensive drugs, Outcome 1 Change in residual kidney function [mL/min/1.73 m²]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009120-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ACEis versus other antihypertensive drugs, Outcome 2 All‐cause mortality." data-id="CD009120-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 ACEis versus other antihypertensive drugs, Outcome 2 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009120-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ACEis versus other antihypertensive drugs, Outcome 3 Cardiovascular events." data-id="CD009120-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 ACEis versus other antihypertensive drugs, Outcome 3 Cardiovascular events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009120-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ACEis versus other antihypertensive drugs, Outcome 4 Anuria." data-id="CD009120-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 ACEis versus other antihypertensive drugs, Outcome 4 Anuria.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009120-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 ACEis versus other antihypertensive drugs, Outcome 5 Peritonitis." data-id="CD009120-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 ACEis versus other antihypertensive drugs, Outcome 5 Peritonitis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009120-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ARBs versus ACEis, Outcome 1 Residual kidney function [mL/min/1.73 m²]." data-id="CD009120-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 ARBs versus ACEis, Outcome 1 Residual kidney function [mL/min/1.73 m²].</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009120-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ARBs versus ACEis, Outcome 2 Cardiovascular events (nonfatal)." data-id="CD009120-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 ARBs versus ACEis, Outcome 2 Cardiovascular events (nonfatal).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009120-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ARBs versus ACEis, Outcome 3 Anuria." data-id="CD009120-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 ARBs versus ACEis, Outcome 3 Anuria.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009120-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ARBs versus ACEis, Outcome 4 Systolic BP." data-id="CD009120-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 ARBs versus ACEis, Outcome 4 Systolic BP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009120-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ARBs versus ACEis, Outcome 5 Diastolic BP." data-id="CD009120-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 ARBs versus ACEis, Outcome 5 Diastolic BP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009120-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ARBs versus ACEis, Outcome 6 Peritonitis." data-id="CD009120-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 ARBs versus ACEis, Outcome 6 Peritonitis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009120-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ARBs versus ACEis, Outcome 7 Cough." data-id="CD009120-fig-0023" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 ARBs versus ACEis, Outcome 7 Cough.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009120-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ARBs versus ACEis, Outcome 8 Serum potassium." data-id="CD009120-fig-0024" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 ARBs versus ACEis, Outcome 8 Serum potassium.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009120-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/urn:x-wiley:14651858:media:CD009120:CD009120-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_t/tCD009120-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ARBs versus ACEis, Outcome 9 Hyperkalaemia." data-id="CD009120-fig-0025" src="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 ARBs versus ACEis, Outcome 9 Hyperkalaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/media/CDSR/CD009120/image_n/nCD009120-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009120-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Angiotensin receptor blockers (ARBs) versus conventional therapy for preserving residual kidney function in peritoneal dialysis patients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ARBs versus conventional therapy for preserving residual kidney function in peritoneal dialysis patients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients receiving PD </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> ARB </p> <p><b>Comparison:</b> Conventional therapy </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Conventional therapy</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>ARBs</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Residual kidney function (3 months)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean across control group was 3.06 mL/min/1.73 m²</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean was on average <b>0.44 mL/min/1.73 m</b> ² <b>lower</b> (95% Cl ‐1.53 to 0.65) in the ARB group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Residual kidney function (6 months)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean across control group was 2.26 mL/min/1.73 m²</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean was on average <b>0.20 mL/min/1.73 m</b> ² <b>lower</b> (95% Cl ‐1.01 to 0.61) in the ARB group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Residual kidney function (≥ 12 months)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean across control groups ranged from 1.04 to 2.8 mL/min/1.73 m²</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean was on average <b>1.11 mL/min/1.73 m</b> ² <b>lower</b> (95% Cl 0.38 to 1.83) in the ARB groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Residual kidney function (12 months)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean across control group was 1.04 mL/min/1.73 m²</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean was on average <b>0.64 mL/min/1.73 m</b> ² <b>higher</b> (95% Cl 0.19 to 1.19) in the ARB group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Residual kidney function (24 months)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean across control groups ranged from 2.57 to 2.8 mL/min/1.73 m²</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean was on average<b>1.49 mL/min/1.73 m</b> ² <b>higher</b> (95% Cl 1.12 to 1.86) in the ARB groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urinary protein excretion</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean across control groups ranged from 1.12 to 2.97 g/24 h</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean was on average<b>0.01 g/24 h lower</b> (95% Cl ‐0.09 to 0.06) in the ARB groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Kt/V</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean Kt/V across control groups ranged from 1.69 to 1.98</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean was on average<b>0.1 higher</b> (95% Cl ‐0.02 to 0.22) in the ARB groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weekly creatinine clearance</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean across control groups from 31.4 to 71.5 L/wk/1.73 m²</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean was on average<b>9.06 L/wk/1.73 m</b> ² <b>higher</b> (95% Cl ‐2.77 to 20.90) in the ARB groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Systolic BP</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean across control groups ranged from 129 to 137 mm Hg</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean was on average<b>‐0.67 mm Hg higher</b> (95% Cl ‐2.77 to 1.42) in the ARB groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diastolic BP</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean across control groups ranged from 129 to 137 mm Hg</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean was on average<b>‐0.70 mm Hg higher</b> (95% Cl ‐2.14 to 0.74) in the ARB groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum potassium</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean across control group was 4.06 mmol/L</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean was on average<b>0.13 mmol/L higher</b> (95% Cl ‐0.12 to 0.38) in the ARB group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events (episodes of peritonitis)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.67</b> (0.18 to 2.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Angiotensin receptor blockers (ARBs) versus conventional therapy for preserving residual kidney function in peritoneal dialysis patients</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/full#CD009120-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009120-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Angiotensin‐converting enzyme inhibitors (ACEi) versus conventional therapy for preserving residual kidney function in peritoneal dialysis patients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ACEi versus conventional therapy for preserving residual kidney function in peritoneal dialysis patients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients receiving PD </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> ACEi </p> <p><b>Comparison:</b> Conventional therapy </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Conventional therapy</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ACEi</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Decline in residual kidney function (12 months)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean across the control group was 1.86 mL/min/1.73 m²</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean was <b>0.93 mL/min/1.73 m</b> ² <b>lower</b>(95% Cl ‐1.75 to ‐0.11) in the ACEi group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Anuria</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>High risk population</b> </p> <p><b>733 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>467 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.32</b> </p> <p>(0.11 to 0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.50</b> </p> <p>(0.27 to 8.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cardiac events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.0</b> </p> <p>(0.37 to 3.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cardiac events (fatal)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.0</b> </p> <p>(0.15 to 6.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cardiac events (non fatal)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.0</b> </p> <p>(0.31 to 3.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events (episodes of peritonitis)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.13</b> </p> <p>(0.47 to 2.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events (episodes of peritonitis) ‐ treated with an aminoglycoside</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.20</b> </p> <p>(0.41 to 3.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events (episodes of peritonitis) ‐ not treated with an aminoglycoside</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.00</b> </p> <p>(0.22 to 4.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Angiotensin‐converting enzyme inhibitors (ACEi) versus conventional therapy for preserving residual kidney function in peritoneal dialysis patients</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/full#CD009120-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009120-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Angiotensin receptor blockers (ARBs) versus angiotensin‐converting enzyme inhibitors (ACEis) for preserving residual kidney function in peritoneal dialysis patients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ARBs compared with ACEis for preserving residual kidney function in peritoneal dialysis patients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients receiving PD </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> ARB </p> <p><b>Comparison:</b> ACEi </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>ACEi</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>ARB</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Residual kidney function (4 weeks)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean across ACEi group was 2.28 mL/min/1.73 m²</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean was <b>0.47 mL/min/1.73 m</b> ² <b>lower</b> (95% Cl ‐2.73 to 1.79) in the ARB group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Residual kidney function (12 months)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean across ACEi group was 2.36 mL/min/1.73 m²</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean was <b>0.18 mL/min/1.73 m</b> ² <b>higher</b> (95% Cl ‐0.04 to 0.40) in the ARB group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Anuria</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>High risk population</b> </p> <p><b>367 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>400 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.15</b> (0.41 to 3.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiovascular events (non‐fatal)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>High risk population</b> </p> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>133 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.33</b> (0.33 to 5.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serum potassium</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean across ACEi group was 4.42 mmol/L</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean was <b>0.05 mmol/L lower</b> (95% Cl ‐2.73 to 1.79) in the ARB group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Systolic BP</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean across ACEi group was 141.95 mm Hg</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean was <b>0.48 mm Hg higher</b> (95% Cl ‐7.76 to 8.72) in the ARB group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Diastolic BP</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean across ACEi group was 84.19 mm Hg</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean was <b>0.38 mm Hg higher</b> (95% Cl ‐6.76 to 7.52) in the ARB group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cough</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>High risk population</b> </p> <p><b>67 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>100 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.56</b> </p> <p>(0.24 to 10.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hyperkalaemia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>High risk population</b> </p> <p><b>69 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>83 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.23</b> (0.35 to 4.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>144 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Angiotensin receptor blockers (ARBs) versus angiotensin‐converting enzyme inhibitors (ACEis) for preserving residual kidney function in peritoneal dialysis patients</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/full#CD009120-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009120-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">ARBs versus other antihypertensive drugs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Residual kidney function [mL/min/1.73 m²] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.44 [‐1.53, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐1.01, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.19, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.12, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 12 to 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.38, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Urinary protein excretion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.09, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Kt/V <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.02, 0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Weekly creatinine clearance [mL/wk/1.73 m²] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.06 [‐2.77, 20.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Systolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.67 [‐2.77, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Diastolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐2.14, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Peritonitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Serum potassium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">ARBs versus other antihypertensive drugs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009120-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">ACEis versus other antihypertensive drugs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in residual kidney function [mL/min/1.73 m²] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.31, 3.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Fatal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.15, 6.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Non‐fatal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.22, 4.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Anuria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Peritonitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 All patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Treated with an aminoglycoside</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Not treated with an aminoglycoside</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">ACEis versus other antihypertensive drugs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009120-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">ARBs versus ACEis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Residual kidney function [mL/min/1.73 m²] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cardiovascular events (nonfatal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Anuria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Systolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Diastolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Peritonitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Cough <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Serum potassium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Hyperkalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.2 [0.40, 3.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">ARBs versus ACEis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009120.pub2/references#CD009120-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009120.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009120-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009120-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009120-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD009120-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD009120-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009120\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009120\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009120\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009120\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009120\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009120\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009120\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009120\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009120\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009120\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009120\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009120\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009120\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009120\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009120\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009120\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009120\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009120\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1pyM3CVc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009120.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009120.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009120.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009120.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009120.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740713754880"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009120.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740713754884"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009120.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d5dfdcdf7936e',t:'MTc0MDcxMzc1NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 